Drug Information

Drug (ID: DG00044) and It's Reported Resistant Information

• Name: Darunavir
• Synonyms: 206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl; Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
• Indication:
  In total 1 Indication(s)
  Human immunodeficiency virus disease [ICD-11: 1C60-1C62]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  HIV infection [ICD-11: 1C62]; [2]
• Target: Human immunodeficiency virus Protease (HIV PR); POL_HV1B1; [1]
• Formula: C27H37N3O7S
• IsoSMILES: CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N
• InChI: 1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
• InChIKey: CJBJHOAVZSMMDJ-HEXNFIEUSA-N
• PubChem CID: 213039
• ChEBI ID: CHEBI:367163
• TTD Drug ID: D03IGH
• VARIDT ID: DR00514
• INTEDE ID: DR0420
• DrugBank ID: DB01264

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

HIV infection [ICD-11: 1C62]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.I13V+p.L19I+p.K20T+p.E35G+p.M36I+p.R41K+p.R57G+p.I62V+p.L63T+p.I64V+p.I72T+p.T74S+p.V77I+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.L10LF+p.K14KR+p.E35D+p.R41RK+p.R57RG+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.L33V+p.R41K+p.I64V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, L33V, R41K, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.I13V+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I13V, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.I15V+p.M36I+p.N37D+p.K43R+p.R57RK+p.L63P+p.I72V+p.P79PS
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I15V, M36I, N37D, K43R, R57RK, L63P, I72V, P79PS.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36I+p.N37D+p.K43KR+p.R57K+p.D60E+p.Q61QE+p.I62IV+p.L63P+p.A71T+p.I72IV+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, N37D, K43KR, R57K, D60E, Q61QE, I62IV, L63P, A71T, I72IV, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.T12TP+p.I13V+p.K14KR+p.K20I+p.E35D+p.M36I+p.N37D+p.M46I+p.I54V+p.L63P+p.A71V+p.I72V+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12TP, I13V, K14KR, K20I, E35D, M36I, N37D, M46I, I54V, L63P, A71V, I72V, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14R+p.L63X+p.I72V+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, L63X, I72V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LF+p.T12E+p.I13V+p.K20KT+p.E35EK+p.M36I+p.N37DE+p.M46MI+p.I62IV+p.I64V+p.L90LM+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, T12E, I13V, K20KT, E35EK, M36I, N37DE, M46MI, I62IV, I64V, L90LM, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.M46L+p.I62V+p.L63P+p.I85V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M46L, I62V, L63P, I85V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19I+p.L63P+p.A71AT+p.I72E
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, L63P, A71AT, I72E.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19LP+p.R41K+p.L63P+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19LP, R41K, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12E+p.I15V+p.L19I+p.E35D+p.M36I+p.R41K+p.I62V+p.L63PS+p.A71AT+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12E, I15V, L19I, E35D, M36I, R41K, I62V, L63PS, A71AT, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I54IM+p.L63P+p.V77VI+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I54IM, L63P, V77VI, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12N+p.K14R+p.I15V+p.G16E+p.K20M+p.M36I+p.P39Q+p.L63S+p.I64V+p.K70R
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, K14R, I15V, G16E, K20M, M36I, P39Q, L63S, I64V, K70R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12E+p.K14KR+p.K43KR+p.R57K+p.L63P+p.A71T
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12E, K14KR, K43KR, R57K, L63P, A71T.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.I15V+p.Q18QK+p.K20RT+p.V32I+p.E35D+p.M36I+p.N37D+p.R57K+p.L63P+p.I64IV+p.A71IMT+p.I72V+p.V77I+p.V82VI+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I15V, Q18QK, K20RT, V32I, E35D, M36I, N37D, R57K, L63P, I64IV, A71IMT, I72V, V77I, V82VI, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.Q7R+p.T12S+p.K14R+p.R41K+p.I62V+p.L63P+p.I64M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q7R, T12S, K14R, R41K, I62V, L63P, I64M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.R41RK+p.M46I+p.D60E+p.I62V+p.L63P+p.I64V+p.K70R+p.I72E+p.G73C+p.V77I+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, R41RK, M46I, D60E, I62V, L63P, I64V, K70R, I72E, G73C, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E34Q+p.N37C+p.R41K+p.M46I+p.I50V+p.I62V+p.L63T+p.A71V+p.L76V+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E34Q, N37C, R41K, M46I, I50V, I62V, L63T, A71V, L76V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.N37D+p.R57K+p.L63P+p.A71T+p.I72V+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57K, L63P, A71T, I72V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.R41RK+p.M46I+p.R57G+p.D60E+p.I62V+p.L63P+p.I64V+p.K70R+p.I72E+p.G73C+p.V77I+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, R41RK, M46I, R57G, D60E, I62V, L63P, I64V, K70R, I72E, G73C, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37S+p.R41K+p.R57G+p.L63A+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R41K, R57G, L63A, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.K14R+p.N37S+p.R41K+p.R57G+p.L63P+p.I64IV+p.H69HQ+p.A71AT+p.I72L+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14R, N37S, R41K, R57G, L63P, I64IV, H69HQ, A71AT, I72L, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.K14KR+p.N37S+p.R41K+p.R57G+p.L63P+p.I64IV+p.H69HQ+p.A71AT+p.I72L+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14KR, N37S, R41K, R57G, L63P, I64IV, H69HQ, A71AT, I72L, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12S+p.I15V+p.L19IV+p.M36I+p.R41K+p.R57G+p.L63P+p.H69K+p.L89M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I15V, L19IV, M36I, R41K, R57G, L63P, H69K, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.L19I+p.R57G+p.L63P+p.C67D+p.V77I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, L19I, R57G, L63P, C67D, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.K70R
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, K70R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L33F+p.M36L+p.P39Q+p.R41K+p.K43R+p.I54V+p.I62V+p.L63P+p.A71V+p.V82L+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33F, M36L, P39Q, R41K, K43R, I54V, I62V, L63P, A71V, V82L, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35D+p.L63P+p.A71AV+p.I72IT+p.V82L+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, L63P, A71AV, I72IT, V82L, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.N37D+p.R57K+p.I62V+p.L63P+p.A71T+p.I72IMT+p.G73S+p.V77I+p.I85V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37D, R57K, I62V, L63P, A71T, I72IMT, G73S, V77I, I85V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.K20R+p.D30N+p.L33I+p.E35D+p.M36I+p.M46L+p.I54V+p.R57K+p.L63P+p.A71V+p.V82A+p.N88D+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20R, D30N, L33I, E35D, M36I, M46L, I54V, R57K, L63P, A71V, V82A, N88D, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12TK+p.N37X+p.R41RK+p.L63Q
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TK, N37X, R41RK, L63Q.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.M46MI+p.L63P+p.I64V+p.K70R+p.I72V+p.V77VI+p.L90M+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, M46MI, L63P, I64V, K70R, I72V, V77VI, L90M, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L19V+p.K20T+p.M46I+p.I54V+p.I62V+p.L63P+p.A71V+p.I72L+p.G73S+p.V82T+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L19V, K20T, M46I, I54V, I62V, L63P, A71V, I72L, G73S, V82T, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.D60E+p.L63P+p.I64V+p.G73C+p.V77I+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, D60E, L63P, I64V, G73C, V77I, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.G16E+p.L63PT+p.T74P+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16E, L63PT, T74P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.K20T+p.L33F+p.M46I+p.Q58E+p.I62V+p.L63P+p.V77I+p.N88G
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20T, L33F, M46I, Q58E, I62V, L63P, V77I, N88G.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.T12TN+p.K14KR+p.L24I+p.L33F+p.M46I+p.I54V+p.I62V+p.L63P+p.H69Q+p.A71I+p.I72L+p.V77I+p.V82T+p.I93M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12TN, K14KR, L24I, L33F, M46I, I54V, I62V, L63P, H69Q, A71I, I72L, V77I, V82T, I93M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.R41K+p.D60E+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R41K, D60E, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14E+p.L63P+p.I64V+p.E65K+p.H69Q+p.I72L+p.V77I+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14E, L63P, I64V, E65K, H69Q, I72L, V77I, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L63P+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L63P+p.H69Q+p.I72V+p.V77I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L63P, H69Q, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.M36I+p.I64V+p.V82L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, I64V, V82L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.I15V+p.Q18K+p.K20T+p.V32I+p.E35D+p.M36I+p.N37D+p.R57K+p.L63P+p.I64V+p.A71T+p.I72IV+p.V77I+p.V82I+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I15V, Q18K, K20T, V32I, E35D, M36I, N37D, R57K, L63P, I64V, A71T, I72IV, V77I, V82I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12S+p.I15V+p.L19I+p.M36I+p.N37D+p.L63V+p.H69K+p.T74A+p.L89M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I15V, L19I, M36I, N37D, L63V, H69K, T74A, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I15V+p.K20T+p.E35D+p.M36I+p.R41K+p.I62V+p.L63P+p.H69K+p.A71T+p.T74S+p.L89I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20T, E35D, M36I, R41K, I62V, L63P, H69K, A71T, T74S, L89I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.I13V+p.K14R+p.L19V+p.K20R+p.M36I+p.R41K+p.R57G+p.L63Q+p.I64V+p.A71V+p.V82M+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, I13V, K14R, L19V, K20R, M36I, R41K, R57G, L63Q, I64V, A71V, V82M, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19T+p.N37D+p.K43R+p.R57G+p.L63X
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19T, N37D, K43R, R57G, L63X.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.R57G+p.I62IV+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R57G, I62IV, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19IV+p.M36MI+p.R57G+p.I64V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19IV, M36MI, R57G, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.E34ED+p.M36MI+p.M46MI+p.I54IL+p.K55R+p.R57K+p.Q58QE+p.I62V+p.L63LP+p.A71T+p.N83NS+p.I84V+p.L89X
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, E34ED, M36MI, M46MI, I54IL, K55R, R57K, Q58QE, I62V, L63LP, A71T, N83NS, I84V, L89X.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.E34ED+p.M36MI+p.M46MI+p.I54IL+p.K55R+p.R57K+p.Q58QE+p.I62V+p.L63LP+p.A71T+p.N83NS+p.I84V+p.L89X
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, E34ED, M36MI, M46MI, I54IL, K55R, R57K, Q58QE, I62V, L63LP, A71T, N83NS, I84V, L89X.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.I15V+p.L19I+p.R41K+p.L63P+p.V77I+p.V82L+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I15V, L19I, R41K, L63P, V77I, V82L, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13V+p.K14KR+p.I15V+p.L24I+p.M36MI+p.N37E+p.M46I+p.I54V+p.L63P+p.A71VI+p.V82AT+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, K14KR, I15V, L24I, M36MI, N37E, M46I, I54V, L63P, A71VI, V82AT, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.M36I+p.I72V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, I72V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.L19I+p.L63P+p.I64IV
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, L19I, L63P, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.E35D+p.M36I+p.N37S+p.R41K+p.M46V+p.G48V+p.I54T+p.D60E+p.I62IV+p.L63P+p.A71IV+p.I72IT+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37S, R41K, M46V, G48V, I54T, D60E, I62IV, L63P, A71IV, I72IT, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10FIV+p.I13IV+p.D30N+p.E35D+p.M36IV+p.N37X+p.R41RK+p.Q58E+p.I62V+p.L63P+p.I64V+p.N88D+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FIV, I13IV, D30N, E35D, M36IV, N37X, R41RK, Q58E, I62V, L63P, I64V, N88D, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.Q18H+p.R41K+p.L63PS+p.A71V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q18H, R41K, L63PS, A71V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12S+p.I62V+p.L63P+p.V77I+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I62V, L63P, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14KR+p.R57K+p.L63P+p.V77I+p.I84IV+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, R57K, L63P, V77I, I84IV, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.G16E+p.N37S+p.I62V+p.L63T+p.I72V+p.V77I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G16E, N37S, I62V, L63T, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I54M+p.L63P+p.H69HY+p.A71V+p.G73GS+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I54M, L63P, H69HY, A71V, G73GS, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63PS+p.V77VI
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63PS, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K20R+p.E35D+p.M36I+p.R41K+p.K43KR+p.R57K+p.D60E+p.I62V+p.L63P+p.A71V+p.I72T+p.P79D+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, E35D, M36I, R41K, K43KR, R57K, D60E, I62V, L63P, A71V, I72T, P79D, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L19I+p.K20R+p.E35D+p.M36I+p.R41K+p.M46I+p.I54V+p.L63P+p.I64V+p.G73T+p.V82A+p.L90M+p.I93L+p.C95F
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, E35D, M36I, R41K, M46I, I54V, L63P, I64V, G73T, V82A, L90M, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14R+p.I15V+p.L63Q+p.I72V+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15V, L63Q, I72V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.I72T
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I72T.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14R+p.I15V+p.R57G+p.L63Q+p.I72V+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15V, R57G, L63Q, I72V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K43T+p.M46L+p.K55R+p.R57G+p.A71V+p.V82A+p.N83P+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K43T, M46L, K55R, R57G, A71V, V82A, N83P, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12LS+p.I15V+p.L19I+p.M36I+p.R41K+p.R57G+p.I62V+p.H69K+p.A71T+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12LS, I15V, L19I, M36I, R41K, R57G, I62V, H69K, A71T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L23I+p.L33LI+p.M36I+p.M46I+p.I54V+p.R57G+p.I62IV+p.L63A+p.A71V+p.T74S+p.V77VI+p.I84IV+p.I85IV+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L23I, L33LI, M36I, M46I, I54V, R57G, I62IV, L63A, A71V, T74S, V77VI, I84IV, I85IV, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12K+p.I13V+p.L19I+p.M36IV+p.R41K+p.R57G+p.I62V+p.L63P+p.I72IM
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12K, I13V, L19I, M36IV, R41K, R57G, I62V, L63P, I72IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L33V+p.N37C+p.R41K+p.R57G+p.L63P+p.I64V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33V, N37C, R41K, R57G, L63P, I64V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37T+p.R57G+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37T, R57G, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.R57G+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R57G, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I15V+p.R41K+p.M46I+p.K55R+p.I62IV+p.L63P+p.A71T+p.G73GS+p.V82T+p.I84V+p.I85V+p.L89LM
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I15V, R41K, M46I, K55R, I62IV, L63P, A71T, G73GS, V82T, I84V, I85V, L89LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.M36I+p.I54V+p.I62IMV+p.L63P+p.A71V+p.V82T+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, M36I, I54V, I62IMV, L63P, A71V, V82T, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12S+p.L19LI+p.L63P+p.I72V+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, L19LI, L63P, I72V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.K14R+p.L63P+p.G68E+p.A71T
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14R, L63P, G68E, A71T.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L24I+p.R41K+p.M46I+p.L63P+p.I64V+p.V82A+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, R41K, M46I, L63P, I64V, V82A, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.G16E+p.D60E+p.Q61QE+p.I62V+p.L63KQ+p.I72EV+p.V77I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, G16E, D60E, Q61QE, I62V, L63KQ, I72EV, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10X+p.E35D+p.M36I+p.N37E+p.R41RK+p.R57RK+p.I62IV+p.I64IV+p.H69HY+p.I84IV
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10X, E35D, M36I, N37E, R41RK, R57RK, I62IV, I64IV, H69HY, I84IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.L19T+p.K20R+p.M36I+p.R41K+p.I62V+p.K70R+p.V82L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L19T, K20R, M36I, R41K, I62V, K70R, V82L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.L19T+p.M36I+p.R41K+p.L63Q+p.H69K+p.I72IM+p.L89LM+p.L90LS+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L19T, M36I, R41K, L63Q, H69K, I72IM, L89LM, L90LS, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LV+p.I15V+p.M36MI+p.N37X+p.R41K+p.L63S+p.I72T
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, I15V, M36MI, N37X, R41K, L63S, I72T.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.N37D+p.L63P+p.A71T+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, L63P, A71T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.K14R+p.R57K+p.L63P+p.I72V+p.V77I+p.L89I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, K14R, R57K, L63P, I72V, V77I, L89I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.A22AV+p.R41K+p.R57G+p.D60E+p.L63P+p.V77I+p.Q92E
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A22AV, R41K, R57G, D60E, L63P, V77I, Q92E.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LFI+p.L19Q+p.K20KR+p.L23LI+p.E35ED+p.M36MI+p.I54IM+p.R57G+p.I62IV+p.L63LP+p.I64V+p.G73GC+p.T74TS+p.V77VI+p.I84IV+p.L90LM+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFI, L19Q, K20KR, L23LI, E35ED, M36MI, I54IM, R57G, I62IV, L63LP, I64V, G73GC, T74TS, V77VI, I84IV, L90LM, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10Y+p.G16E+p.V32I+p.L33LI+p.E35D+p.M36I+p.N37V+p.M46V+p.I47V+p.F53L+p.K55KR+p.R57G+p.L63A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10Y, G16E, V32I, L33LI, E35D, M36I, N37V, M46V, I47V, F53L, K55KR, R57G, L63A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.I15V+p.R41K+p.R57G+p.L63Q+p.A71V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, I15V, R41K, R57G, L63Q, A71V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L24LI+p.L33LF+p.M36MIL+p.R41K+p.M46ML+p.G48GV+p.I54IV+p.K55KR+p.R57G+p.Q58E+p.I62IV+p.L63P+p.I64IV+p.G73AT+p.V82VA+p.I84IV+p.L90LM+p.T91TA
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24LI, L33LF, M36MIL, R41K, M46ML, G48GV, I54IV, K55KR, R57G, Q58E, I62IV, L63P, I64IV, G73AT, V82VA, I84IV, L90LM, T91TA.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LV+p.T12TKN+p.K14KR+p.I15V+p.L19I+p.R41K+p.R57G+p.L63CS+p.E65ED+p.V77I+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, T12TKN, K14KR, I15V, L19I, R41K, R57G, L63CS, E65ED, V77I, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.E35D+p.M36I+p.R41K+p.R57G+p.I62V+p.L63P+p.I64V+p.I85V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, R41K, R57G, I62V, L63P, I64V, I85V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13IV+p.L33V+p.E35D+p.L63P+p.R87RG
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13IV, L33V, E35D, L63P, R87RG.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L24F+p.M46I+p.D60E+p.I62V+p.L63P+p.A71V+p.I72V+p.G73S+p.V77I+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24F, M46I, D60E, I62V, L63P, A71V, I72V, G73S, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.L63T+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L63T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57RK+p.L63P+p.E65ED+p.A71T+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57RK, L63P, E65ED, A71T, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36MI+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36MI, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L24I+p.M46L+p.G48V+p.I54V+p.L63P+p.A71V+p.V77I+p.V82A
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, M46L, G48V, I54V, L63P, A71V, V77I, V82A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.L63P
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.L33LF+p.M36I+p.R41K+p.M46MIL+p.L63T+p.V82VI+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L33LF, M36I, R41K, M46MIL, L63T, V82VI, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T4P+p.L10V+p.I13AV+p.L19P+p.K20I+p.E35G+p.M36I+p.N37S+p.R41K+p.M46I+p.I54IV+p.L63LP+p.H69K+p.K70R+p.A71T+p.G73GS+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4P, L10V, I13AV, L19P, K20I, E35G, M36I, N37S, R41K, M46I, I54IV, L63LP, H69K, K70R, A71T, G73GS, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.K20R+p.V32I+p.E35D+p.M36I+p.N37S+p.R41K+p.L63P+p.I64V+p.C67CW+p.A71V+p.I85IV+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K20R, V32I, E35D, M36I, N37S, R41K, L63P, I64V, C67CW, A71V, I85IV, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.I15V+p.Q18QK+p.K20RT+p.V32I+p.E35D+p.M36I+p.N37D+p.R57K+p.L63P+p.I64IV+p.A71IMT+p.I72V+p.V77I+p.V82VI+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I15V, Q18QK, K20RT, V32I, E35D, M36I, N37D, R57K, L63P, I64IV, A71IMT, I72V, V77I, V82VI, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.K20R+p.D30N+p.L33F+p.E35D+p.M36I+p.N37D+p.R41K+p.I54V+p.R57G+p.L63P+p.I64V+p.N88D+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20R, D30N, L33F, E35D, M36I, N37D, R41K, I54V, R57G, L63P, I64V, N88D, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.Q7QR+p.L10LV+p.I13IV+p.K14R+p.E35D+p.N37DE+p.P39PS+p.R57K+p.I62IV+p.L63P+p.I64V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q7QR, L10LV, I13IV, K14R, E35D, N37DE, P39PS, R57K, I62IV, L63P, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.K20R+p.E35D+p.M36I+p.N37D+p.R41K+p.R57K+p.V82I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20R, E35D, M36I, N37D, R41K, R57K, V82I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [4]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.E35D+p.M36I+p.R41K+p.R57K+p.H69K+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, E35D, M36I, R41K, R57K, H69K, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20I+p.E35D+p.M36I+p.M46I+p.I62V+p.L63P+p.I64V+p.A71V+p.I72V+p.L76V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20I, E35D, M36I, M46I, I62V, L63P, I64V, A71V, I72V, L76V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R41K+p.Q58QH+p.L63P+p.I72IM+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, Q58QH, L63P, I72IM, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K20T+p.E35N+p.M36I+p.N37E+p.I62V+p.L63P+p.K70R+p.A71I+p.T74S+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20T, E35N, M36I, N37E, I62V, L63P, K70R, A71I, T74S, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.L24I+p.M46I+p.I54V+p.K55KR+p.R57G+p.Q58E+p.D60E+p.L63P+p.I64V+p.I72V+p.V77I+p.V82A
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, L24I, M46I, I54V, K55KR, R57G, Q58E, D60E, L63P, I64V, I72V, V77I, V82A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.K20T+p.D30N+p.E35D+p.M36I+p.K43KT+p.R57G+p.Q58E+p.I62V+p.L63P+p.V77I+p.N88D
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20T, D30N, E35D, M36I, K43KT, R57G, Q58E, I62V, L63P, V77I, N88D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.A22V+p.R57G+p.L63P+p.A71V+p.I72L+p.G73S+p.V77I+p.I84V+p.I85V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, A22V, R57G, L63P, A71V, I72L, G73S, V77I, I84V, I85V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.E35D+p.M36I+p.R41K+p.I62V+p.L63P+p.A71V+p.T74P+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, R41K, I62V, L63P, A71V, T74P, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.L19I+p.K20R+p.E35D+p.M36I+p.N37E+p.R41K+p.I54V+p.Q58E+p.D60N+p.I62V+p.L63P+p.K70R+p.A71V+p.G73S+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19I, K20R, E35D, M36I, N37E, R41K, I54V, Q58E, D60N, I62V, L63P, K70R, A71V, G73S, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K14R+p.G16E+p.K20I+p.E35D+p.M36I+p.N37D+p.R41N+p.I54V+p.L63H+p.H69K+p.K70R+p.T74S+p.L76V+p.V82A+p.L89I+p.T91S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14R, G16E, K20I, E35D, M36I, N37D, R41N, I54V, L63H, H69K, K70R, T74S, L76V, V82A, L89I, T91S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.E35D+p.M36I+p.N37S+p.R41K+p.R57G+p.I62V+p.L63P+p.A71V+p.G73S+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, N37S, R41K, R57G, I62V, L63P, A71V, G73S, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.L63Q
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63Q.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K20M+p.L33I+p.E35D+p.N37A+p.K43R+p.R57K+p.L63H+p.L89I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20M, L33I, E35D, N37A, K43R, R57K, L63H, L89I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.G16GE+p.L19V+p.M36L+p.N37ND+p.R57K+p.L63LP
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, G16GE, L19V, M36L, N37ND, R57K, L63LP.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14KR+p.G16GE+p.G17GE+p.R57K+p.L63T+p.A71T+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14KR, G16GE, G17GE, R57K, L63T, A71T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12TK+p.L33F+p.K43T+p.M46I+p.I50L+p.I54V+p.K55R+p.I62V+p.L63P+p.A71V+p.I72L+p.G73T+p.V77I+p.V82A+p.L90M+p.I93L+p.C95F
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TK, L33F, K43T, M46I, I50L, I54V, K55R, I62V, L63P, A71V, I72L, G73T, V77I, V82A, L90M, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.T12Q+p.I13M+p.K20I+p.M46I+p.I54V+p.Q58E+p.L63P+p.I64V+p.C67FL+p.H69R+p.G73T+p.V77I+p.V82A+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12Q, I13M, K20I, M46I, I54V, Q58E, L63P, I64V, C67FL, H69R, G73T, V77I, V82A, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.W6WR+p.L10FI+p.I13V+p.M46MI+p.I54IV+p.L63AP+p.C67CF+p.A71T+p.I72IV+p.I84IV+p.N88ND+p.L90LM+p.I93L+p.C95CF
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, L10FI, I13V, M46MI, I54IV, L63AP, C67CF, A71T, I72IV, I84IV, N88ND, L90LM, I93L, C95CF.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.D30N+p.L33F+p.M46L+p.F53L+p.I54L+p.Q58E+p.L63P+p.A71T+p.G73S+p.V77I+p.N88D
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, D30N, L33F, M46L, F53L, I54L, Q58E, L63P, A71T, G73S, V77I, N88D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10FI+p.I13IV+p.K14KR+p.G16GA+p.D30DN+p.L33LF+p.N37NH+p.M46MI+p.I54V+p.R57K+p.L63P+p.G68GE+p.K70KE+p.A71AV+p.V82A+p.N88ND+p.Q92QK+p.I93IL+p.G94X
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, I13IV, K14KR, G16GA, D30DN, L33LF, N37NH, M46MI, I54V, R57K, L63P, G68GE, K70KE, A71AV, V82A, N88ND, Q92QK, I93IL, G94X.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.G16E+p.L19I+p.K20R+p.L24I+p.E35D+p.M36I+p.I54V+p.I62V+p.L63C+p.A71V+p.V82T+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, G16E, L19I, K20R, L24I, E35D, M36I, I54V, I62V, L63C, A71V, V82T, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.K20T+p.D30N+p.E35D+p.M36I+p.K43KT+p.R57G+p.Q58E+p.I62V+p.L63P+p.V77I+p.N88D
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20T, D30N, E35D, M36I, K43KT, R57G, Q58E, I62V, L63P, V77I, N88D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.Q18H+p.L19V+p.K20R+p.L33I+p.M36I+p.N37S+p.R57G+p.L63P+p.I64V+p.I84V+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, Q18H, L19V, K20R, L33I, M36I, N37S, R57G, L63P, I64V, I84V, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [4]

• Molecule Alteration: Missense mutation; p.I13IV+p.I15V+p.R41K+p.F53FL+p.I64V+p.H69Y
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15V, R41K, F53FL, I64V, H69Y.

Key Molecule: HIV1 Protease (HIV1 PR) [4]

• Molecule Alteration: Missense mutation; p.T4TN+p.I13V+p.L33F+p.M36I+p.R41K+p.R57K+p.E65D+p.H69K+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TN, I13V, L33F, M36I, R41K, R57K, E65D, H69K, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.L19LI+p.V32VI+p.L33F+p.N37T+p.M46MI+p.I50IL+p.I54IV+p.I62IMV+p.I64IV+p.A71AV+p.V82VA+p.I84IV
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L19LI, V32VI, L33F, N37T, M46MI, I50IL, I54IV, I62IMV, I64IV, A71AV, V82VA, I84IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.L24I+p.L33F+p.M36MI+p.M46I+p.L63P+p.A71V+p.P79D+p.V82T+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L24I, L33F, M36MI, M46I, L63P, A71V, P79D, V82T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.L19LI+p.M36MI+p.N37NS+p.R41K+p.I54IV+p.Q58QE+p.I62V+p.L63DN+p.A71AV+p.I72IT+p.V82VA+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L19LI, M36MI, N37NS, R41K, I54IV, Q58QE, I62V, L63DN, A71AV, I72IT, V82VA, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I15V+p.K20I+p.E35Q+p.M36I+p.N37D+p.R41K+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20I, E35Q, M36I, N37D, R41K, R57K, C67E, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.T12PS+p.L19I+p.V32I+p.E35D+p.M36I+p.R41RK+p.M46ML+p.I47A+p.Q61QH+p.L63P+p.I64V+p.A71AV+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12PS, L19I, V32I, E35D, M36I, R41RK, M46ML, I47A, Q61QH, L63P, I64V, A71AV, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.M46I+p.R57K+p.I62V+p.L63P+p.A71T+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, M46I, R57K, I62V, L63P, A71T, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.N37ND+p.K45KR+p.M46I+p.R57G+p.I62IV+p.L63P+p.K70R+p.A71IT+p.I72T+p.G73S+p.V82T+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, N37ND, K45KR, M46I, R57G, I62IV, L63P, K70R, A71IT, I72T, G73S, V82T, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.K20T+p.E35D+p.M36I+p.M46I+p.I54V+p.K55KR+p.R57RK+p.Q58E+p.D60DE+p.I62V+p.L63P+p.A71T+p.I72IT+p.N83ND+p.I85V+p.N88S+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20T, E35D, M36I, M46I, I54V, K55KR, R57RK, Q58E, D60DE, I62V, L63P, A71T, I72IT, N83ND, I85V, N88S, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.K20R+p.L33F+p.M36I+p.M46L+p.I54LV+p.L63P+p.A71V+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, K20R, L33F, M36I, M46L, I54LV, L63P, A71V, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.I13IV+p.K14R+p.L19V+p.K20R+p.M36MI+p.R41K+p.M46I+p.R57G+p.L63HQ+p.I64V+p.V82L+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, I13IV, K14R, L19V, K20R, M36MI, R41K, M46I, R57G, L63HQ, I64V, V82L, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L33F+p.K43T+p.M46I+p.G48V+p.F53Y+p.I54S+p.R57G+p.D60E+p.Q61E+p.I62V+p.L63T+p.A71V+p.I72V+p.T74P+p.V82A+p.L89M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, K43T, M46I, G48V, F53Y, I54S, R57G, D60E, Q61E, I62V, L63T, A71V, I72V, T74P, V82A, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.K20M+p.L63P+p.A71V+p.G73S+p.P79AD+p.I84V+p.R87RK+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20M, L63P, A71V, G73S, P79AD, I84V, R87RK, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12K+p.I15V+p.N37H+p.R41RK+p.K55N+p.L63P+p.A71V+p.V77I+p.I84V+p.I85V+p.N88D+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12K, I15V, N37H, R41RK, K55N, L63P, A71V, V77I, I84V, I85V, N88D, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.L24I+p.M46L+p.I54V+p.L63P+p.A71V+p.V77I+p.V82A+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L24I, M46L, I54V, L63P, A71V, V77I, V82A, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I3IV+p.L10I+p.V11VI+p.I13V+p.I15V+p.K20M+p.E35G+p.M36I+p.I54V+p.R57G+p.D60E+p.I62V+p.L63P+p.A71V+p.N88D+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3IV, L10I, V11VI, I13V, I15V, K20M, E35G, M36I, I54V, R57G, D60E, I62V, L63P, A71V, N88D, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12I+p.N37D+p.M46L+p.G48V+p.R57K+p.L63Q+p.I64V+p.A71V+p.I72T+p.V82A+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12I, N37D, M46L, G48V, R57K, L63Q, I64V, A71V, I72T, V82A, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13V+p.G16A+p.L33F+p.R41RK+p.M46L+p.I54V+p.Q58E+p.I62V+p.L63P+p.I66F+p.A71V+p.I72L+p.G73S+p.V77I+p.P79PA+p.V82T+p.I84IV+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, G16A, L33F, R41RK, M46L, I54V, Q58E, I62V, L63P, I66F, A71V, I72L, G73S, V77I, P79PA, V82T, I84IV, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.E35D+p.M36I+p.N37D+p.R41K+p.M46I+p.I54V+p.I62V+p.L63P+p.V82A+p.L90M+p.I93L+p.C95F
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37D, R41K, M46I, I54V, I62V, L63P, V82A, L90M, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.I13IV+p.E35D+p.M36I+p.R41K+p.M46L+p.L63P+p.A71V+p.I84V+p.L90M+p.Q92K+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13IV, E35D, M36I, R41K, M46L, L63P, A71V, I84V, L90M, Q92K, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L33F+p.K43T+p.L63C+p.H69Q+p.V77I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33F, K43T, L63C, H69Q, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13V+p.G16E+p.K20R+p.D30N+p.L33F+p.E35D+p.M36I+p.N37T+p.K45R+p.I54V+p.R57K+p.Q58E+p.I62IV+p.L63T+p.E65D+p.I72V+p.V82A+p.N88D
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, G16E, K20R, D30N, L33F, E35D, M36I, N37T, K45R, I54V, R57K, Q58E, I62IV, L63T, E65D, I72V, V82A, N88D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L24I+p.L33F+p.N37S+p.M46L+p.I54V+p.K55KR+p.I62IV+p.L63P+p.A71V+p.I72IM+p.G73GCS+p.V82A
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, L33F, N37S, M46L, I54V, K55KR, I62IV, L63P, A71V, I72IM, G73GCS, V82A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20R+p.L33F+p.E34KR+p.E35D+p.M36I+p.G40GE+p.R41K+p.K43T+p.G48M+p.I54S+p.I62V+p.I72IMT+p.V82A
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, L33F, E34KR, E35D, M36I, G40GE, R41K, K43T, G48M, I54S, I62V, I72IMT, V82A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.E35D+p.M36I+p.G48V+p.I50V+p.I54V+p.I62V+p.L63A+p.A71V+p.V82T
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, G48V, I50V, I54V, I62V, L63A, A71V, V82T.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.L33I+p.M36I+p.R41K+p.M46L+p.I54L+p.L63P+p.I64V+p.N88D
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L33I, M36I, R41K, M46L, I54L, L63P, I64V, N88D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K20KR+p.V32I+p.E35D+p.M36I+p.K43T+p.M46I+p.R57G+p.L63P+p.A71V+p.V82A+p.I84IV+p.L90LM
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, V32I, E35D, M36I, K43T, M46I, R57G, L63P, A71V, V82A, I84IV, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.K14R+p.I15V+p.M36I+p.G48V+p.I54V+p.D60E+p.I62V+p.I64V+p.T74A+p.V82A+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, K14R, I15V, M36I, G48V, I54V, D60E, I62V, I64V, T74A, V82A, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13IV+p.V32I+p.E35D+p.M36MI+p.N37S+p.K43T+p.M46I+p.I47V+p.L63P+p.V77VI+p.V82T+p.I85V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, V32I, E35D, M36MI, N37S, K43T, M46I, I47V, L63P, V77VI, V82T, I85V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.L19I+p.K20R+p.M36I+p.R41K+p.M46L+p.I54V+p.L63P+p.A71V+p.L76V+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19I, K20R, M36I, R41K, M46L, I54V, L63P, A71V, L76V, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.V32I+p.M46I+p.I47V+p.I62V+p.L63P+p.I72Y+p.G73S+p.V77I+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V32I, M46I, I47V, I62V, L63P, I72Y, G73S, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.V32VI+p.L33M+p.R41K+p.K43KR+p.M46I+p.I62V+p.L63P+p.C67CF+p.A71IT+p.I72V+p.G73GC+p.T74P+p.V77I+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, V32VI, L33M, R41K, K43KR, M46I, I62V, L63P, C67CF, A71IT, I72V, G73GC, T74P, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14R+p.I15IV+p.E35D+p.M36I+p.R41K+p.M46L+p.I54V+p.Q58E+p.I62V+p.L63P+p.C67F+p.H69HR+p.A71V+p.I72KR+p.G73S+p.V82A+p.L90M+p.C95L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15IV, E35D, M36I, R41K, M46L, I54V, Q58E, I62V, L63P, C67F, H69HR, A71V, I72KR, G73S, V82A, L90M, C95L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.T12TK+p.K20I+p.M36I+p.N37D+p.R57K+p.I62V+p.L63P+p.G73C+p.I84V+p.I85V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12TK, K20I, M36I, N37D, R57K, I62V, L63P, G73C, I84V, I85V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L33F+p.M36L+p.P39Q+p.R41K+p.K43R+p.M46I+p.I47V+p.F53L+p.I54V+p.I62V+p.L63P+p.A71V+p.V82L+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33F, M36L, P39Q, R41K, K43R, M46I, I47V, F53L, I54V, I62V, L63P, A71V, V82L, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.N37D+p.K43KT+p.M46MI+p.G48LV+p.F53FY+p.I54S+p.I62V+p.L63P+p.H69Y+p.A71V+p.T74S+p.V77I+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, N37D, K43KT, M46MI, G48LV, F53FY, I54S, I62V, L63P, H69Y, A71V, T74S, V77I, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [5]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.G16A+p.Q18H+p.L33F+p.N37D+p.M46I+p.I54V+p.Q61H+p.I62IV+p.L63P+p.A71L+p.I72T+p.L76V+p.V77I+p.V82VA+p.N88G+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, Q18H, L33F, N37D, M46I, I54V, Q61H, I62IV, L63P, A71L, I72T, L76V, V77I, V82VA, N88G, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13IV+p.L24F+p.L33F+p.E35D+p.M36I+p.N37ND+p.R41RK+p.K43KT+p.M46MI+p.I54V+p.K55KR+p.I62V+p.L63P+p.A71V+p.I72IV+p.G73S+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, L24F, L33F, E35D, M36I, N37ND, R41RK, K43KT, M46MI, I54V, K55KR, I62V, L63P, A71V, I72IV, G73S, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.N37ND+p.R41K+p.M46I+p.I47V+p.L63P+p.A71T+p.I72V+p.V77I+p.N88G+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, N37ND, R41K, M46I, I47V, L63P, A71T, I72V, V77I, N88G, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.E35D+p.M36I+p.N37D+p.M46L+p.G48V+p.I54V+p.D60E+p.I62V+p.L63P+p.A71V+p.I72V+p.V77I+p.V82S+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37D, M46L, G48V, I54V, D60E, I62V, L63P, A71V, I72V, V77I, V82S, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [6]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.T12P+p.I13V+p.I15V+p.L19P+p.K20T+p.V32I+p.L33F+p.E35G+p.M36I+p.I54IV+p.I62V+p.L63P+p.K70T+p.A71I+p.G73S+p.P79A+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, I15V, L19P, K20T, V32I, L33F, E35G, M36I, I54IV, I62V, L63P, K70T, A71I, G73S, P79A, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [7]

• Molecule Alteration: Missense mutation; p.L10IM+p.I13V+p.Q18H+p.N37D+p.M46I+p.K55KR+p.Q61QH+p.L63P+p.A71T+p.I72T+p.V77I+p.N88S+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IM, I13V, Q18H, N37D, M46I, K55KR, Q61QH, L63P, A71T, I72T, V77I, N88S, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.T12V+p.E35D+p.M36I+p.R41K+p.R57K+p.Q61N
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12V, E35D, M36I, R41K, R57K, Q61N.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20I+p.M36I+p.R41K+p.I64M+p.H69K+p.K70R+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, M36I, R41K, I64M, H69K, K70R, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20I+p.E35D+p.M36I+p.R41K+p.H69K+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, E35D, M36I, R41K, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13A+p.K14R+p.K20I+p.M36I+p.N37D+p.R41K+p.H69K+p.L89I
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13A, K14R, K20I, M36I, N37D, R41K, H69K, L89I.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.K14R+p.L19P+p.K20I+p.M36I+p.R41K+p.L63P+p.H69K+p.K70R+p.I72M+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K14R, L19P, K20I, M36I, R41K, L63P, H69K, K70R, I72M, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20I+p.E35Q+p.M36I+p.N37D+p.R41K+p.K43R+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, E35Q, M36I, N37D, R41K, K43R, R57K, C67E, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20I+p.E35D+p.M36I+p.R41K+p.I62IV+p.L63LHP+p.H69K+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, E35D, M36I, R41K, I62IV, L63LHP, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14KR+p.I15IV+p.K20I+p.M36I+p.R41K+p.I64M+p.H69K+p.K70R+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14KR, I15IV, K20I, M36I, R41K, I64M, H69K, K70R, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.L19P+p.K20I+p.E35D+p.M36I+p.R41K+p.H69K+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, L19P, K20I, E35D, M36I, R41K, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K14R+p.I15V+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14R, I15V, K20I, E35Q, M36I, R41K, R57K, C67E, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.T12N+p.K14R+p.I15V+p.L19IM+p.K20R+p.E35D+p.M36I+p.R41K+p.R57K+p.L63T+p.E65D+p.I72T+p.G73GD+p.T74S+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, K14R, I15V, L19IM, K20R, E35D, M36I, R41K, R57K, L63T, E65D, I72T, G73GD, T74S, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10V+p.I15V+p.E35D+p.M36I+p.R41K+p.R57K+p.Q61DN+p.L63CS+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, E35D, M36I, R41K, R57K, Q61DN, L63CS, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [7]

• Molecule Alteration: Missense mutation; p.L10F+p.E35D+p.L63P+p.A71V+p.T74P+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, E35D, L63P, A71V, T74P, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I15V+p.G17D+p.K20R+p.E35D+p.M36I+p.R41K+p.R57K+p.Q61N+p.E65D+p.I72T
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, G17D, K20R, E35D, M36I, R41K, R57K, Q61N, E65D, I72T.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10M+p.I13V+p.K14R+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.C67E+p.H69K+p.V82VI+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10M, I13V, K14R, K20I, E35Q, M36I, R41K, R57K, C67E, H69K, V82VI, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [7]

• Molecule Alteration: Missense mutation; p.L10IV+p.V32VI+p.M46I+p.I47V+p.L63P+p.V77I+p.Q92QKR+p.I93L+p.C95F
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, V32VI, M46I, I47V, L63P, V77I, Q92QKR, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.V32I+p.L33F+p.M36L+p.K43T+p.M46V+p.I54V+p.K55R+p.R57RK+p.L63P+p.I64V+p.A71V+p.V82A+p.N83D+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, V32I, L33F, M36L, K43T, M46V, I54V, K55R, R57RK, L63P, I64V, A71V, V82A, N83D, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37D+p.M46L+p.I54V+p.L63P+p.A71T+p.V82A+p.T91S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L24I, L33F, E35D, M36I, N37D, M46L, I54V, L63P, A71T, V82A, T91S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M46L+p.K55R+p.L63P+p.H69Y+p.A71T+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M46L, K55R, L63P, H69Y, A71T, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.K20T+p.L33F+p.E35N+p.M36IL+p.N37ND+p.R41KN+p.M46L+p.I50L+p.R57K+p.Q58E+p.I62V+p.L63P+p.I64V+p.A71V+p.T74S+p.V82M+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20T, L33F, E35N, M36IL, N37ND, R41KN, M46L, I50L, R57K, Q58E, I62V, L63P, I64V, A71V, T74S, V82M, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.L63S+p.C67E+p.H69K+p.V82I+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, E35Q, M36I, R41K, R57K, L63S, C67E, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L33F+p.E35D+p.K43T+p.I54L+p.L63P+p.I64L+p.V77I+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, E35D, K43T, I54L, L63P, I64L, V77I, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10FI+p.V11VI+p.I13V+p.I15V+p.Q18QH+p.K20I+p.M36I+p.N37D+p.M46L+p.I54M+p.L63P+p.A71IV+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, V11VI, I13V, I15V, Q18QH, K20I, M36I, N37D, M46L, I54M, L63P, A71IV, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.I54L+p.I62V+p.L63P+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, I54L, I62V, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.Q18H+p.L19V+p.K20R+p.L33I+p.M36I+p.N37S+p.K45KR+p.I62IV+p.L63P+p.I64V+p.A71AV+p.N83ND+p.I84V+p.T91TS+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, Q18H, L19V, K20R, L33I, M36I, N37S, K45KR, I62IV, L63P, I64V, A71AV, N83ND, I84V, T91TS, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.L24I+p.E35D+p.M36I+p.N37E+p.M46I+p.I54V+p.Q61N+p.I62V+p.L63P+p.I64V+p.A71V+p.I72V+p.T74S+p.L76V+p.V82T+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L24I, E35D, M36I, N37E, M46I, I54V, Q61N, I62V, L63P, I64V, A71V, I72V, T74S, L76V, V82T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13V+p.I15IV+p.K20R+p.L33F+p.E34D+p.E35D+p.M36I+p.K45R+p.I54V+p.R57K+p.I62V+p.L63P+p.I66V+p.A71V+p.G73S+p.V82A+p.I84V+p.I85L+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, I15IV, K20R, L33F, E34D, E35D, M36I, K45R, I54V, R57K, I62V, L63P, I66V, A71V, G73S, V82A, I84V, I85L, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.L24I+p.E35D+p.N37DE+p.M46I+p.I54V+p.R57RK+p.Q61H+p.I62V+p.L63P+p.I64V+p.A71V+p.I72V+p.T74S+p.L76V+p.V82T+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L24I, E35D, N37DE, M46I, I54V, R57RK, Q61H, I62V, L63P, I64V, A71V, I72V, T74S, L76V, V82T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.E35D+p.M36I+p.K43T+p.I47V+p.G48M+p.F53L+p.I54V+p.I62V+p.L63P+p.I66F+p.A71V+p.V82T+p.I84V+p.Q92R
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, K43T, I47V, G48M, F53L, I54V, I62V, L63P, I66F, A71V, V82T, I84V, Q92R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L33I+p.E35G+p.M36I+p.R41K+p.M46MI+p.I54V+p.K55KR+p.R57RK+p.Q58E+p.D60E+p.L63P+p.A71T+p.I72IV+p.G73S+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33I, E35G, M36I, R41K, M46MI, I54V, K55KR, R57RK, Q58E, D60E, L63P, A71T, I72IV, G73S, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.I13V+p.G16A+p.L33F+p.N37D+p.M46L+p.I54V+p.R57G+p.I62V+p.L63P+p.I72L+p.G73S+p.V77I+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, G16A, L33F, N37D, M46L, I54V, R57G, I62V, L63P, I72L, G73S, V77I, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.N37S+p.M46I+p.I62V+p.L63P+p.A71V+p.T74P+p.V77I+p.I84V+p.L90M+p.Q92R+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37S, M46I, I62V, L63P, A71V, T74P, V77I, I84V, L90M, Q92R, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L19I+p.K20M+p.V32I+p.L33LF+p.M36I+p.M46I+p.I47V+p.F53L+p.I54V+p.I62V+p.L63A+p.I64IM+p.A71V+p.V82A+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20M, V32I, L33LF, M36I, M46I, I47V, F53L, I54V, I62V, L63A, I64IM, A71V, V82A, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LFV+p.L33LI+p.N37NH+p.M46I+p.I54V+p.D60E+p.I62V+p.L63P+p.I64IV+p.I66V+p.I72IT+p.G73T+p.V77I+p.I84V+p.I85V+p.L90M+p.I93L+p.C95V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFV, L33LI, N37NH, M46I, I54V, D60E, I62V, L63P, I64IV, I66V, I72IT, G73T, V77I, I84V, I85V, L90M, I93L, C95V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.T12TP+p.I13V+p.K20KR+p.E35D+p.M36I+p.R41K+p.M46L+p.I62IV+p.L63P+p.A71V+p.I84V+p.L90M+p.Q92K+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12TP, I13V, K20KR, E35D, M36I, R41K, M46L, I62IV, L63P, A71V, I84V, L90M, Q92K, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T4P+p.L10F+p.Q18QH+p.L19I+p.L33F+p.E34Q+p.N37D+p.M46I+p.I54L+p.L63P+p.A71I+p.I72L+p.V77I+p.N88G+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4P, L10F, Q18QH, L19I, L33F, E34Q, N37D, M46I, I54L, L63P, A71I, I72L, V77I, N88G, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.I15V+p.D30N+p.L33F+p.E35D+p.M36L+p.N37D+p.K45I+p.F53FL+p.I54V+p.I62V+p.L63P+p.V82A+p.N88D+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, I15V, D30N, L33F, E35D, M36L, N37D, K45I, F53FL, I54V, I62V, L63P, V82A, N88D, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L33F+p.G48V+p.I54S+p.Q58QE+p.D60E+p.L63P+p.A71V+p.V77I+p.V82A+p.T91A
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, G48V, I54S, Q58QE, D60E, L63P, A71V, V77I, V82A, T91A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V32VI+p.L33LF+p.E34EQ+p.I47IV+p.I54IM+p.D60E+p.L63P+p.K70T+p.A71AV+p.I72IK+p.G73GS+p.V77I+p.L90LM+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V32VI, L33LF, E34EQ, I47IV, I54IM, D60E, L63P, K70T, A71AV, I72IK, G73GS, V77I, L90LM, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13IM+p.K14KR+p.K20I+p.L24I+p.E35D+p.M36I+p.R41K+p.M46L+p.G48GA+p.I54V+p.K55KR+p.D60E+p.I62V+p.L63P+p.I64IV+p.A71V+p.V82A+p.I84V+p.T91TS
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13IM, K14KR, K20I, L24I, E35D, M36I, R41K, M46L, G48GA, I54V, K55KR, D60E, I62V, L63P, I64IV, A71V, V82A, I84V, T91TS.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LF+p.G16A+p.L19I+p.G27GE+p.L33F+p.N37NS+p.M46I+p.G51A+p.K55R+p.Q58E+p.D60E+p.L63P+p.A71V+p.I72IM+p.G73S+p.V77I+p.V82A+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, G16A, L19I, G27GE, L33F, N37NS, M46I, G51A, K55R, Q58E, D60E, L63P, A71V, I72IM, G73S, V77I, V82A, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.V32I+p.L33F+p.E34K+p.E35D+p.M36V+p.N37S+p.M46I+p.I47V+p.G48E+p.I54M+p.R57K+p.Q58E+p.I62V+p.L63P+p.A71T+p.V77T+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, V32I, L33F, E34K, E35D, M36V, N37S, M46I, I47V, G48E, I54M, R57K, Q58E, I62V, L63P, A71T, V77T, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13V+p.L33I+p.E35D+p.M36I+p.I47IM+p.I54V+p.Q58QE+p.I62V+p.L63P+p.A71V+p.V82F+p.I85IV+p.L89V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, L33I, E35D, M36I, I47IM, I54V, Q58QE, I62V, L63P, A71V, V82F, I85IV, L89V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.I15V+p.K20V+p.L33F+p.E35D+p.M36I+p.N37E+p.M46I+p.I54V+p.R57G+p.Q61QE+p.I62V+p.L63P+p.A71AT+p.I72IL+p.G73CS+p.V75VI+p.V82A+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, I15V, K20V, L33F, E35D, M36I, N37E, M46I, I54V, R57G, Q61QE, I62V, L63P, A71AT, I72IL, G73CS, V75VI, V82A, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13V+p.L33F+p.E34ED+p.M36MV+p.M46L+p.I54V+p.Q58E+p.D60E+p.I62V+p.L63P+p.I66IV+p.K70KT+p.A71M+p.I72IM+p.V77I+p.V82T+p.I84V+p.L89M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, L33F, E34ED, M36MV, M46L, I54V, Q58E, D60E, I62V, L63P, I66IV, K70KT, A71M, I72IM, V77I, V82T, I84V, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.V32I+p.E35D+p.M36I+p.R41RK+p.K43T+p.M46I+p.I47V+p.F53FL+p.I54V+p.K55R+p.L63P+p.A71V+p.V82A+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, V32I, E35D, M36I, R41RK, K43T, M46I, I47V, F53FL, I54V, K55R, L63P, A71V, V82A, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.L23I+p.L24M+p.N37NH+p.K43KT+p.M46I+p.F53L+p.I54V+p.K55R+p.D60E+p.I62V+p.L63P+p.A71V+p.I72V+p.G73ST+p.V77I+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, L23I, L24M, N37NH, K43KT, M46I, F53L, I54V, K55R, D60E, I62V, L63P, A71V, I72V, G73ST, V77I, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.V32I+p.L33F+p.E34Q+p.M46I+p.I47V+p.F53L+p.I54V+p.K55KR+p.L63P+p.A71V+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, V32I, L33F, E34Q, M46I, I47V, F53L, I54V, K55KR, L63P, A71V, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.K20R+p.V32I+p.M36I+p.M46I+p.I47IV+p.F53L+p.I54V+p.L63P+p.A71I+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20R, V32I, M36I, M46I, I47IV, F53L, I54V, L63P, A71I, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10C+p.T12K+p.I13V+p.K20T+p.V32I+p.L33V+p.M36I+p.K43I+p.M46I+p.I47V+p.I62IV+p.L63P+p.A71V+p.V82T+p.I84V+p.L89V+p.L90LM+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10C, T12K, I13V, K20T, V32I, L33V, M36I, K43I, M46I, I47V, I62IV, L63P, A71V, V82T, I84V, L89V, L90LM, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.I15IV+p.Q18H+p.K20V+p.A22AV+p.L33LIV+p.M36I+p.M46MI+p.I54V+p.K55KR+p.R57K+p.I62V+p.L63P+p.C67W+p.A71V+p.I72L+p.G73S+p.I84V+p.I85IV+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15IV, Q18H, K20V, A22AV, L33LIV, M36I, M46MI, I54V, K55KR, R57K, I62V, L63P, C67W, A71V, I72L, G73S, I84V, I85IV, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.V32VI+p.L33F+p.E35D+p.M36MI+p.R41K+p.I47IV+p.K55N+p.R57K+p.L63P+p.I64M+p.A71AV+p.L90M+p.I93IL
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, V32VI, L33F, E35D, M36MI, R41K, I47IV, K55N, R57K, L63P, I64M, A71AV, L90M, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20I+p.L33V+p.E35D+p.M36I+p.N37T+p.M46I+p.I54V+p.Q58QE+p.I62V+p.L63P+p.I64IV+p.A71V+p.T74P+p.V82L+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, L33V, E35D, M36I, N37T, M46I, I54V, Q58QE, I62V, L63P, I64IV, A71V, T74P, V82L, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13IV+p.I15V+p.L19I+p.V32I+p.L33LF+p.M46I+p.I47A+p.K55KN+p.Q58QE+p.L63P+p.K70KE+p.A71V+p.V77I+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13IV, I15V, L19I, V32I, L33LF, M46I, I47A, K55KN, Q58QE, L63P, K70KE, A71V, V77I, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.G16A+p.L19IT+p.K20T+p.M46I+p.I54V+p.R57G+p.L63P+p.A71V+p.I72L+p.G73S+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, G16A, L19IT, K20T, M46I, I54V, R57G, L63P, A71V, I72L, G73S, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.I13V+p.I15IV+p.Q18H+p.K20I+p.N37NT+p.M46I+p.I54V+p.L63P+p.A71V+p.I72M+p.G73S+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, I15IV, Q18H, K20I, N37NT, M46I, I54V, L63P, A71V, I72M, G73S, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.Q18QH+p.L24LF+p.L33F+p.N37X+p.I54V+p.Q58E+p.L63P+p.A71I+p.I72L+p.G73AT+p.V77I+p.V82F+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, Q18QH, L24LF, L33F, N37X, I54V, Q58E, L63P, A71I, I72L, G73AT, V77I, V82F, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.L19P+p.D30N+p.L33F+p.E35D+p.M36I+p.K43T+p.M46I+p.I54V+p.K55R+p.R57K+p.I62V+p.L63P+p.A71T+p.I72IM+p.V75I+p.V82A+p.N88D+p.L89V+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19P, D30N, L33F, E35D, M36I, K43T, M46I, I54V, K55R, R57K, I62V, L63P, A71T, I72IM, V75I, V82A, N88D, L89V, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T4TA+p.L10F+p.I15IV+p.K20KT+p.E35D+p.M46I+p.I54V+p.L63P+p.I64V+p.A71V+p.I72L+p.G73T+p.V77VI+p.I84V+p.I85V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TA, L10F, I15IV, K20KT, E35D, M46I, I54V, L63P, I64V, A71V, I72L, G73T, V77VI, I84V, I85V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.V32I+p.L33I+p.M36I+p.I54V+p.L63P+p.A71I+p.I85V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, V32I, L33I, M36I, I54V, L63P, A71I, I85V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.L33F+p.E34Q+p.K43T+p.M46L+p.I54V+p.L63P+p.K70KR+p.A71AV+p.T74S+p.V77I+p.P79S+p.I84V+p.N88D+p.L89M+p.L90M+p.T91S+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L33F, E34Q, K43T, M46L, I54V, L63P, K70KR, A71AV, T74S, V77I, P79S, I84V, N88D, L89M, L90M, T91S, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11L+p.I13V+p.I15V+p.Q18H+p.K20I+p.E35G+p.M36I+p.N37D+p.I54V+p.L63P+p.A71V+p.I72L+p.G73GS+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, I13V, I15V, Q18H, K20I, E35G, M36I, N37D, I54V, L63P, A71V, I72L, G73GS, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T4S+p.V11I+p.I13V+p.L19V+p.K20IV+p.L33V+p.E35D+p.M36I+p.N37NS+p.M46IL+p.I54V+p.K55R+p.R57K+p.L63P+p.I64V+p.C67F+p.H69R+p.A71I+p.I72F+p.G73T+p.P79A+p.V82VL+p.I84V+p.L90M+p.I93L+p.T96S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4S, V11I, I13V, L19V, K20IV, L33V, E35D, M36I, N37NS, M46IL, I54V, K55R, R57K, L63P, I64V, C67F, H69R, A71I, I72F, G73T, P79A, V82VL, I84V, L90M, I93L, T96S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14R+p.V32I+p.R41K+p.G48M+p.F53L+p.I54M+p.I62V+p.L63A+p.C67D+p.H69R+p.A71L+p.I72V+p.V77I+p.V82A+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, V32I, R41K, G48M, F53L, I54M, I62V, L63A, C67D, H69R, A71L, I72V, V77I, V82A, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.G16A+p.L33F+p.K45R+p.I54L+p.K55R+p.I62V+p.L63P+p.C67CY+p.I72L+p.G73C+p.V77I+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16A, L33F, K45R, I54L, K55R, I62V, L63P, C67CY, I72L, G73C, V77I, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L33F+p.R41K+p.M46L+p.I54V+p.K55R+p.Q58E+p.D60E+p.Q61E+p.L63P+p.A71T+p.I72T+p.G73C+p.V82A+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, R41K, M46L, I54V, K55R, Q58E, D60E, Q61E, L63P, A71T, I72T, G73C, V82A, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13IV+p.I15V+p.L33F+p.E34Q+p.M36L+p.N37D+p.R41RK+p.M46L+p.G48V+p.I54T+p.I62V+p.L63P+p.A71V+p.I72V+p.T74D+p.V75I+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13IV, I15V, L33F, E34Q, M36L, N37D, R41RK, M46L, G48V, I54T, I62V, L63P, A71V, I72V, T74D, V75I, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K43S+p.M46I+p.I54V+p.R57K+p.I62V+p.L63P+p.A71V+p.G73T+p.V77I+p.V82F+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K43S, M46I, I54V, R57K, I62V, L63P, A71V, G73T, V77I, V82F, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.I15IV+p.L19V+p.L33F+p.K43KT+p.K45KR+p.I54V+p.I62IV+p.L63P+p.A71V+p.T74P+p.V82L+p.I84V+p.L90M+p.I93IM
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15IV, L19V, L33F, K43KT, K45KR, I54V, I62IV, L63P, A71V, T74P, V82L, I84V, L90M, I93IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L19I+p.K20R+p.E35D+p.M36I+p.K43KE+p.M46L+p.G48V+p.I54CST+p.R57K+p.Q58E+p.I62V+p.L63P+p.A71V+p.I72V+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, E35D, M36I, K43KE, M46L, G48V, I54CST, R57K, Q58E, I62V, L63P, A71V, I72V, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.G16A+p.L19Q+p.V32I+p.N37S+p.R41K+p.K45R+p.M46I+p.I47A+p.L63P+p.A71V+p.I72V+p.V82A+p.L90M+p.Q92K+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16A, L19Q, V32I, N37S, R41K, K45R, M46I, I47A, L63P, A71V, I72V, V82A, L90M, Q92K, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.T12P+p.I13V+p.I15V+p.L19P+p.K20I+p.E35G+p.M36I+p.M46I+p.I54V+p.L63P+p.A71V+p.I72L+p.G73S+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, I15V, L19P, K20I, E35G, M36I, M46I, I54V, L63P, A71V, I72L, G73S, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.I13V+p.A22V+p.V32I+p.R41K+p.M46I+p.K55R+p.I62V+p.L63P+p.I64V+p.H69Q+p.A71V+p.V82A+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, A22V, V32I, R41K, M46I, K55R, I62V, L63P, I64V, H69Q, A71V, V82A, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LFI+p.V11VI+p.I13V+p.L33F+p.E35D+p.N37D+p.M46L+p.I54L+p.Q58E+p.I62V+p.L63P+p.A71T+p.I72V+p.L90M+p.Q92R
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFI, V11VI, I13V, L33F, E35D, N37D, M46L, I54L, Q58E, I62V, L63P, A71T, I72V, L90M, Q92R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.K20I+p.L24I+p.V32VI+p.M36I+p.M46I+p.I54V+p.D60E+p.I64V+p.I66V+p.A71F+p.I72T+p.G73C+p.I84V+p.T91S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20I, L24I, V32VI, M36I, M46I, I54V, D60E, I64V, I66V, A71F, I72T, G73C, I84V, T91S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.I15V+p.V32I+p.L33F+p.L63P+p.C67F+p.A71V+p.G73S+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15V, V32I, L33F, L63P, C67F, A71V, G73S, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.N37X+p.M46I+p.I54ILM+p.I62V+p.L63P+p.I64V+p.A71V+p.I72IT+p.L76V+p.V77I+p.I84V+p.I85V+p.G86GR+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37X, M46I, I54ILM, I62V, L63P, I64V, A71V, I72IT, L76V, V77I, I84V, I85V, G86GR, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.E35D+p.M36I+p.N37E+p.G48V+p.I50V+p.I54A+p.R57RK+p.I62V+p.L63P+p.A71V+p.I72V+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37E, G48V, I50V, I54A, R57RK, I62V, L63P, A71V, I72V, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.I13V+p.Q18H+p.K20I+p.M46I+p.I54L+p.L63P+p.A71V+p.I72IM+p.G73GS+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, Q18H, K20I, M46I, I54L, L63P, A71V, I72IM, G73GS, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.K20I+p.L24I+p.M36I+p.M46I+p.I54V+p.D60E+p.L63P+p.I64V+p.I66V+p.A71T+p.I72T+p.G73C+p.I84V+p.T91S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20I, L24I, M36I, M46I, I54V, D60E, L63P, I64V, I66V, A71T, I72T, G73C, I84V, T91S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.I15V+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37E+p.K45R+p.G48GA+p.F53FI+p.I54V+p.R57K+p.Y59YC+p.I62V+p.L63P+p.G68E+p.A71T+p.I72T+p.G73C+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, K20R, L24I, L33F, E35D, M36I, N37E, K45R, G48GA, F53FI, I54V, R57K, Y59YC, I62V, L63P, G68E, A71T, I72T, G73C, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13M+p.L19LI+p.K20I+p.M36I+p.N37S+p.M46I+p.I54V+p.I62V+p.L63P+p.I64IV+p.I66V+p.C67F+p.H69HQ+p.I72IT+p.G73T+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13M, L19LI, K20I, M36I, N37S, M46I, I54V, I62V, L63P, I64IV, I66V, C67F, H69HQ, I72IT, G73T, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11VI+p.T12TP+p.I13IV+p.I15IV+p.K20X+p.L33F+p.E35D+p.M36L+p.N37D+p.K43KT+p.M46L+p.I62V+p.L63P+p.C67F+p.H69HY+p.A71V+p.I72ILM+p.G73S+p.V82A+p.I84V+p.I85V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, T12TP, I13IV, I15IV, K20X, L33F, E35D, M36L, N37D, K43KT, M46L, I62V, L63P, C67F, H69HY, A71V, I72ILM, G73S, V82A, I84V, I85V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.K20T+p.L24I+p.D30N+p.L33F+p.E35D+p.M36I+p.N37S+p.K43T+p.F53L+p.K55N+p.L63P+p.V77VI+p.N88D+p.L89M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20T, L24I, D30N, L33F, E35D, M36I, N37S, K43T, F53L, K55N, L63P, V77VI, N88D, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IT+p.I13V+p.V32I+p.L33F+p.M36I+p.R41RK+p.M46MIL+p.I47A+p.L63P+p.K70E+p.A71V+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IT, I13V, V32I, L33F, M36I, R41RK, M46MIL, I47A, L63P, K70E, A71V, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.K14R+p.I15V+p.K20T+p.D30N+p.L33F+p.E35D+p.M36I+p.R41I+p.K43RS+p.I54L+p.R57K+p.I62V+p.L63P+p.I66V+p.A71V+p.I72T+p.V77I+p.N88D+p.L90M+p.Q92K+p.I93L+p.C95F+p.T96S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K14R, I15V, K20T, D30N, L33F, E35D, M36I, R41I, K43RS, I54L, R57K, I62V, L63P, I66V, A71V, I72T, V77I, N88D, L90M, Q92K, I93L, C95F, T96S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13IV+p.L33F+p.N37S+p.R41K+p.K43R+p.M46ML+p.I54V+p.K55R+p.R57K+p.I62V+p.L63P+p.I64IM+p.A71V+p.G73S+p.V82C+p.L89V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13IV, L33F, N37S, R41K, K43R, M46ML, I54V, K55R, R57K, I62V, L63P, I64IM, A71V, G73S, V82C, L89V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10FI+p.K20R+p.L33F+p.E35D+p.M36I+p.N37D+p.I54V+p.I62V+p.L63P+p.I64L+p.A71V+p.G73T+p.V82VI+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, K20R, L33F, E35D, M36I, N37D, I54V, I62V, L63P, I64L, A71V, G73T, V82VI, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12P+p.L19V+p.L33F+p.M46L+p.G48M+p.I54M+p.L63T+p.A71V+p.I72T+p.T74A+p.V82A+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, L19V, L33F, M46L, G48M, I54M, L63T, A71V, I72T, T74A, V82A, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.T12P+p.I13V+p.L24F+p.L33F+p.E34Q+p.N37S+p.R41K+p.M46I+p.I54V+p.R57G+p.I62V+p.L63P+p.A71V+p.I72IT+p.G73S+p.P79D+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12P, I13V, L24F, L33F, E34Q, N37S, R41K, M46I, I54V, R57G, I62V, L63P, A71V, I72IT, G73S, P79D, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.K20KR+p.L33F+p.E34ED+p.M36MV+p.N37ND+p.M46I+p.I54MV+p.I62V+p.L63P+p.I66F+p.C67F+p.I72L+p.G73T+p.V75I+p.I84V+p.L90M+p.I93IM+p.C95V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20KR, L33F, E34ED, M36MV, N37ND, M46I, I54MV, I62V, L63P, I66F, C67F, I72L, G73T, V75I, I84V, L90M, I93IM, C95V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.T12X+p.K14KR+p.I15IV+p.Q18QE+p.K20KR+p.V32I+p.L33LF+p.E34EQ+p.E35ED+p.M36I+p.M46I+p.I47A+p.R57K+p.L63P+p.A71V+p.I72V+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12X, K14KR, I15IV, Q18QE, K20KR, V32I, L33LF, E34EQ, E35ED, M36I, M46I, I47A, R57K, L63P, A71V, I72V, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12TI+p.I13V+p.L19LI+p.K20R+p.L33F+p.E35D+p.M36I+p.N37D+p.K43T+p.M46L+p.I54V+p.K55KR+p.I62V+p.L63P+p.A71IV+p.I72IT+p.G73S+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TI, I13V, L19LI, K20R, L33F, E35D, M36I, N37D, K43T, M46L, I54V, K55KR, I62V, L63P, A71IV, I72IT, G73S, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L33F+p.E35D+p.M36I+p.P39PL+p.K43KT+p.F53PS+p.I54L+p.R57G+p.Q58E+p.I62V+p.A71V+p.T74S+p.V82F+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, E35D, M36I, P39PL, K43KT, F53PS, I54L, R57G, Q58E, I62V, A71V, T74S, V82F, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10Y+p.V11VI+p.I13V+p.Q18QH+p.K20IM+p.E21ED+p.L24LIM+p.L33I+p.M36I+p.R41RK+p.M46I+p.I47IV+p.F53FL+p.I54M+p.I62V+p.L63P+p.I64V+p.I72IM+p.G73V+p.T74PS+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10Y, V11VI, I13V, Q18QH, K20IM, E21ED, L24LIM, L33I, M36I, R41RK, M46I, I47IV, F53FL, I54M, I62V, L63P, I64V, I72IM, G73V, T74PS, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.L33I+p.M36I+p.I54V+p.Q58E+p.D60E+p.L63P+p.A71V+p.V82L+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L33I, M36I, I54V, Q58E, D60E, L63P, A71V, V82L, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12S+p.I13V+p.K20R+p.L33LF+p.E35D+p.M36I+p.N37E+p.K43IT+p.I54L+p.R57K+p.I62V+p.L63P+p.K70KE+p.A71I+p.V82A+p.I84V+p.L89V+p.L90M+p.Q92K+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12S, I13V, K20R, L33LF, E35D, M36I, N37E, K43IT, I54L, R57K, I62V, L63P, K70KE, A71I, V82A, I84V, L89V, L90M, Q92K, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10Y+p.I13V+p.K20R+p.L33F+p.E35D+p.M36L+p.R41K+p.K43KT+p.I62V+p.L63P+p.A71V+p.I72M+p.G73S+p.P79HQ+p.V82L+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10Y, I13V, K20R, L33F, E35D, M36L, R41K, K43KT, I62V, L63P, A71V, I72M, G73S, P79HQ, V82L, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11VI+p.I13IV+p.K20R+p.V32VI+p.L33F+p.E35D+p.M36I+p.N37D+p.K43KT+p.M46LS+p.I54L+p.K55R+p.R57K+p.I62V+p.L63T+p.A71V+p.I72V+p.T74PS+p.V82X+p.I84IV+p.L89LF+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, I13IV, K20R, V32VI, L33F, E35D, M36I, N37D, K43KT, M46LS, I54L, K55R, R57K, I62V, L63T, A71V, I72V, T74PS, V82X, I84IV, L89LF, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20R+p.V32VI+p.L33F+p.E34N+p.E35D+p.M36I+p.N37ND+p.P39S+p.R41K+p.K43T+p.I47V+p.I54M+p.I62V+p.L63PT+p.I64V+p.A71T+p.T74S+p.V77I+p.V82T+p.I84V+p.I85IV+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, V32VI, L33F, E34N, E35D, M36I, N37ND, P39S, R41K, K43T, I47V, I54M, I62V, L63PT, I64V, A71T, T74S, V77I, V82T, I84V, I85IV, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.K20R+p.V32I+p.E35D+p.M36I+p.K43T+p.M46I+p.I47V+p.F53L+p.I62V+p.L63P+p.A71L+p.I72V+p.V77Q+p.V82C+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20R, V32I, E35D, M36I, K43T, M46I, I47V, F53L, I62V, L63P, A71L, I72V, V77Q, V82C, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L24I+p.V32VI+p.L33F+p.N37ND+p.M46I+p.I54L+p.I62IV+p.L63P+p.A71V+p.G73V+p.T74P+p.V82A+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24I, V32VI, L33F, N37ND, M46I, I54L, I62IV, L63P, A71V, G73V, T74P, V82A, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11L+p.I13V+p.K14R+p.A22V+p.E35D+p.M36I+p.N37D+p.G48M+p.F53L+p.I54V+p.I62V+p.L63P+p.A71V+p.T74S+p.V82A+p.I84V+p.T91S+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, I13V, K14R, A22V, E35D, M36I, N37D, G48M, F53L, I54V, I62V, L63P, A71V, T74S, V82A, I84V, T91S, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.E21D+p.A22V+p.L24M+p.E35DN+p.M36I+p.N37D+p.R41RK+p.M46L+p.I54V+p.R57RK+p.Q61HN+p.I62V+p.L63P+p.I64V+p.I66V+p.A71V+p.I72T+p.G73T+p.N83D+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, E21D, A22V, L24M, E35DN, M36I, N37D, R41RK, M46L, I54V, R57RK, Q61HN, I62V, L63P, I64V, I66V, A71V, I72T, G73T, N83D, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.V11VI+p.I15IV+p.K20I+p.E34Q+p.M46I+p.I47V+p.F53FL+p.I54M+p.R57G+p.D60E+p.Q61H+p.L63P+p.A71V+p.G73T+p.V77I+p.P79DN+p.I84V+p.I85V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, I15IV, K20I, E34Q, M46I, I47V, F53FL, I54M, R57G, D60E, Q61H, L63P, A71V, G73T, V77I, P79DN, I84V, I85V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13M+p.K20I+p.M36I+p.N37D+p.M46I+p.I54V+p.I62V+p.L63P+p.I66IV+p.C67F+p.A71T+p.I72T+p.G73T+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13M, K20I, M36I, N37D, M46I, I54V, I62V, L63P, I66IV, C67F, A71T, I72T, G73T, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L24I+p.L33F+p.E35D+p.M36I+p.N37S+p.M46I+p.I54M+p.L63P+p.A71V+p.V82VI+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24I, L33F, E35D, M36I, N37S, M46I, I54M, L63P, A71V, V82VI, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L19V+p.L24I+p.V32I+p.L33F+p.K43E+p.M46L+p.I54V+p.D60E+p.L63P+p.A71V+p.I72V+p.V82A+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L19V, L24I, V32I, L33F, K43E, M46L, I54V, D60E, L63P, A71V, I72V, V82A, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L33F+p.M46I+p.F53L+p.I54L+p.I62V+p.L63P+p.A71V+p.T74P+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, M46I, F53L, I54L, I62V, L63P, A71V, T74P, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.L33F+p.E35D+p.M36I+p.I54L+p.I62V+p.L63P+p.A71V+p.G73S+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, L33F, E35D, M36I, I54L, I62V, L63P, A71V, G73S, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.L19I+p.K20R+p.L23I+p.E35D+p.M36I+p.R41K+p.M46I+p.I50V+p.F53L+p.I54V+p.L63P+p.I64V+p.I66V+p.A71I+p.G73T+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, L19I, K20R, L23I, E35D, M36I, R41K, M46I, I50V, F53L, I54V, L63P, I64V, I66V, A71I, G73T, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.K20KR+p.V32I+p.L33LI+p.M36IL+p.N37D+p.M46I+p.F53L+p.R57G+p.I62V+p.L63P+p.K70KNT+p.A71I+p.V82A+p.I85IM+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20KR, V32I, L33LI, M36IL, N37D, M46I, F53L, R57G, I62V, L63P, K70KNT, A71I, V82A, I85IM, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20R+p.L33F+p.E35D+p.M36I+p.N37E+p.K43T+p.M46I+p.I54V+p.R57K+p.D60E+p.Q61E+p.I62V+p.L63P+p.I64IV+p.G68E+p.A71T+p.I72T+p.G73AT+p.V82F+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, L33F, E35D, M36I, N37E, K43T, M46I, I54V, R57K, D60E, Q61E, I62V, L63P, I64IV, G68E, A71T, I72T, G73AT, V82F, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20R+p.L24I+p.L33F+p.E34V+p.E35D+p.M36I+p.N37E+p.G48M+p.I50V+p.F53L+p.I54A+p.R57G+p.D60E+p.I62V+p.L63P+p.A71V+p.V77I+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, L24I, L33F, E34V, E35D, M36I, N37E, G48M, I50V, F53L, I54A, R57G, D60E, I62V, L63P, A71V, V77I, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.L19I+p.K20I+p.L33V+p.E35D+p.M36I+p.N37D+p.R41K+p.K45KR+p.M46I+p.I47A+p.F53Y+p.I62V+p.I64V+p.T74S+p.I84V+p.I85IV+p.L89I+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19I, K20I, L33V, E35D, M36I, N37D, R41K, K45KR, M46I, I47A, F53Y, I62V, I64V, T74S, I84V, I85IV, L89I, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.V32I+p.L33F+p.N37S+p.P39PS+p.R41RK+p.I54L+p.R57G+p.L63PS+p.A71V+p.P79X+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, V32I, L33F, N37S, P39PS, R41RK, I54L, R57G, L63PS, A71V, P79X, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L19I+p.K20R+p.E34D+p.E35D+p.M36I+p.R41K+p.M46I+p.I47V+p.I54M+p.L63P+p.A71T+p.I84V+p.I85V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, E34D, E35D, M36I, R41K, M46I, I47V, I54M, L63P, A71T, I84V, I85V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LV+p.V32I+p.L33M+p.R41K+p.M46I+p.I47V+p.I54M+p.K55KR+p.Q58E+p.L63P+p.K70T+p.A71V+p.T74TP+p.V82T+p.L89F+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, V32I, L33M, R41K, M46I, I47V, I54M, K55KR, Q58E, L63P, K70T, A71V, T74TP, V82T, L89F, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T4TS+p.L10F+p.V11I+p.T12P+p.I13V+p.I15IV+p.K20IT+p.L24M+p.E35D+p.M36I+p.M46I+p.F53FL+p.Q58QE+p.I62V+p.L63E+p.C67CY+p.A71I+p.I72T+p.G73S+p.T74P+p.P79AG+p.I84AV+p.L89V+p.L90M+p.Q92K+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TS, L10F, V11I, T12P, I13V, I15IV, K20IT, L24M, E35D, M36I, M46I, F53FL, Q58QE, I62V, L63E, C67CY, A71I, I72T, G73S, T74P, P79AG, I84AV, L89V, L90M, Q92K, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15IV+p.K20R+p.E35D+p.M36I+p.M46L+p.I54V+p.Q58E+p.D60E+p.Q61E+p.I62IV+p.L63P+p.I64V+p.E65ED+p.I66IV+p.A71V+p.V82F+p.I84V+p.I85V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IV, K20R, E35D, M36I, M46L, I54V, Q58E, D60E, Q61E, I62IV, L63P, I64V, E65ED, I66IV, A71V, V82F, I84V, I85V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.T12P+p.I13V+p.K20I+p.L24M+p.E35D+p.M36I+p.M46I+p.Q61QR+p.I62V+p.L63E+p.C67Y+p.A71I+p.I72T+p.G73S+p.T74P+p.P79A+p.I84V+p.L89V+p.L90M+p.Q92K+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, K20I, L24M, E35D, M36I, M46I, Q61QR, I62V, L63E, C67Y, A71I, I72T, G73S, T74P, P79A, I84V, L89V, L90M, Q92K, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.I15V+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37S+p.R41K+p.K43IT+p.M46I+p.I47V+p.F53L+p.R57K+p.L63P+p.A71V+p.G73S+p.V82A+p.L90M+p.I93L+p.C95CF
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, I15V, K20R, V32I, L33F, E35D, M36I, N37S, R41K, K43IT, M46I, I47V, F53L, R57K, L63P, A71V, G73S, V82A, L90M, I93L, C95CF.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.I15V+p.K20V+p.E34QR+p.E35D+p.M36I+p.N37S+p.R41K+p.G48I+p.I54L+p.K55R+p.Q58E+p.D60NS+p.I62V+p.L63P+p.A71I+p.I72IM+p.G73S+p.L76V+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I15V, K20V, E34QR, E35D, M36I, N37S, R41K, G48I, I54L, K55R, Q58E, D60NS, I62V, L63P, A71I, I72IM, G73S, L76V, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.I15V+p.L19V+p.L24I+p.V32I+p.L33F+p.K43E+p.M46L+p.I54L+p.D60E+p.L63P+p.A71V+p.I72V+p.V82A+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, L19V, L24I, V32I, L33F, K43E, M46L, I54L, D60E, L63P, A71V, I72V, V82A, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L5F+p.L10I+p.I13V+p.G16GA+p.K20KR+p.V32I+p.L33F+p.E35ED+p.M36I+p.N37D+p.K43T+p.M46I+p.I47V+p.F53L+p.I54L+p.D60E+p.L63P+p.A71M+p.G73S+p.V82I+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L5F, L10I, I13V, G16GA, K20KR, V32I, L33F, E35ED, M36I, N37D, K43T, M46I, I47V, F53L, I54L, D60E, L63P, A71M, G73S, V82I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13IV+p.V32I+p.L33F+p.K43KT+p.I54L+p.L63P+p.A71V+p.G73T+p.V77I+p.P79A+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, V32I, L33F, K43KT, I54L, L63P, A71V, G73T, V77I, P79A, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.D30N+p.L33F+p.K45R+p.I54L+p.L63P+p.I66IV+p.P79PS+p.I84V+p.N88D+p.L89LF+p.L90M+p.I93L+p.C95CF
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, D30N, L33F, K45R, I54L, L63P, I66IV, P79PS, I84V, N88D, L89LF, L90M, I93L, C95CF.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11VI+p.I13V+p.I15V+p.K20KR+p.V32I+p.L33M+p.N37T+p.K43I+p.I54V+p.D60N+p.I62V+p.L63P+p.I64V+p.A71V+p.T74E+p.V82L+p.I84V+p.Q92R
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, I13V, I15V, K20KR, V32I, L33M, N37T, K43I, I54V, D60N, I62V, L63P, I64V, A71V, T74E, V82L, I84V, Q92R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.K14R+p.G16E+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37E+p.P39PT+p.R41K+p.K43KIT+p.M46I+p.R57K+p.I62V+p.L63AT+p.A71I+p.V77T+p.V82A+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K14R, G16E, K20R, V32I, L33F, E35D, M36I, N37E, P39PT, R41K, K43KIT, M46I, R57K, I62V, L63AT, A71I, V77T, V82A, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12N+p.I13V+p.L33F+p.M46L+p.I54IV+p.Q61QH+p.L63P+p.I64V+p.A71V+p.T74P+p.V77I+p.V82F+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12N, I13V, L33F, M46L, I54IV, Q61QH, L63P, I64V, A71V, T74P, V77I, V82F, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V32I+p.L33F+p.P39PS+p.M46MI+p.I47V+p.L63P+p.A71I+p.I72KR+p.G73S+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V32I, L33F, P39PS, M46MI, I47V, L63P, A71I, I72KR, G73S, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.L33F+p.E34A+p.E35D+p.M36I+p.N37D+p.K43T+p.M46I+p.G48V+p.I50V+p.I54T+p.I62V+p.L63P+p.A71V+p.I72V+p.V77I+p.V82A+p.I85V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L33F, E34A, E35D, M36I, N37D, K43T, M46I, G48V, I50V, I54T, I62V, L63P, A71V, I72V, V77I, V82A, I85V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12P+p.I15V+p.K20R+p.V32VI+p.M36I+p.N37D+p.M46L+p.I54L+p.L63P+p.A71V+p.T74TS+p.P79S+p.V82VA+p.I84V+p.I85V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, I15V, K20R, V32VI, M36I, N37D, M46L, I54L, L63P, A71V, T74TS, P79S, V82VA, I84V, I85V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.G16A+p.K20KR+p.L24F+p.V32I+p.L33F+p.M36MI+p.R41RK+p.K43T+p.M46I+p.F53L+p.K55KR+p.L63P+p.A71V+p.T74P+p.V77VI+p.V82A+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, K20KR, L24F, V32I, L33F, M36MI, R41RK, K43T, M46I, F53L, K55KR, L63P, A71V, T74P, V77VI, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V32I+p.L33F+p.K43Q+p.I47V+p.I54M+p.R57G+p.L63P+p.A71V+p.G73S+p.V77I+p.V82M+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V32I, L33F, K43Q, I47V, I54M, R57G, L63P, A71V, G73S, V77I, V82M, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.I15V+p.G16A+p.K20R+p.V32I+p.L33F+p.M36I+p.K43T+p.M46I+p.I47V+p.I54M+p.L63P+p.A71V+p.V82T+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, I15V, G16A, K20R, V32I, L33F, M36I, K43T, M46I, I47V, I54M, L63P, A71V, V82T, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11VL+p.I13IV+p.V32I+p.L33F+p.K43T+p.M46I+p.I47V+p.F53L+p.I54L+p.K55KR+p.D60DE+p.I62V+p.L63P+p.I66L+p.C67CW+p.A71T+p.I72T+p.G73C+p.V77I+p.V82C+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11VL, I13IV, V32I, L33F, K43T, M46I, I47V, F53L, I54L, K55KR, D60DE, I62V, L63P, I66L, C67CW, A71T, I72T, G73C, V77I, V82C, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.G16GA+p.K20KR+p.V32I+p.L33F+p.M36MIL+p.N37ND+p.M46I+p.I47V+p.I54M+p.Q58E+p.L63P+p.A71V+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, G16GA, K20KR, V32I, L33F, M36MIL, N37ND, M46I, I47V, I54M, Q58E, L63P, A71V, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.I13V+p.I15V+p.G16A+p.K20I+p.L23I+p.E34D+p.E35K+p.M36I+p.N37D+p.K43T+p.M46I+p.I47IV+p.G51A+p.F53L+p.K55R+p.R57G+p.I62V+p.L63P+p.A71I+p.G73S+p.L76V+p.L89V+p.L90M+p.T91S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, I15V, G16A, K20I, L23I, E34D, E35K, M36I, N37D, K43T, M46I, I47IV, G51A, F53L, K55R, R57G, I62V, L63P, A71I, G73S, L76V, L89V, L90M, T91S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.V32I+p.L33F+p.E34Q+p.M36A+p.P39S+p.M46I+p.F53L+p.I54L+p.K55KR+p.I62V+p.L63P+p.A71V+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V32I, L33F, E34Q, M36A, P39S, M46I, F53L, I54L, K55KR, I62V, L63P, A71V, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I3F+p.L10I+p.K20R+p.V32I+p.L33F+p.E34K+p.E35D+p.M36I+p.N37D+p.R41K+p.K43E+p.K45R+p.I54M+p.D60K+p.L63P+p.A71V+p.I72T+p.V77I+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3F, L10I, K20R, V32I, L33F, E34K, E35D, M36I, N37D, R41K, K43E, K45R, I54M, D60K, L63P, A71V, I72T, V77I, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.I13IV+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37Q+p.M46I+p.I47V+p.I54L+p.R57K+p.Q58E+p.D60E+p.I62V+p.L63P+p.A71V+p.G73S+p.V77T+p.I84V+p.L89V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13IV, K20R, V32I, L33F, E35D, M36I, N37Q, M46I, I47V, I54L, R57K, Q58E, D60E, I62V, L63P, A71V, G73S, V77T, I84V, L89V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11VI+p.T12TA+p.I13V+p.K14KR+p.K20R+p.D30N+p.V32I+p.L33F+p.E35D+p.M36V+p.N37T+p.K43Q+p.M46I+p.I47V+p.F53L+p.I54L+p.K55KR+p.R57K+p.I62V+p.L63P+p.I66IV+p.C67W+p.A71V+p.I72V+p.V77I+p.I84V+p.I85IL+p.N88D+p.L89LV+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11VI, T12TA, I13V, K14KR, K20R, D30N, V32I, L33F, E35D, M36V, N37T, K43Q, M46I, I47V, F53L, I54L, K55KR, R57K, I62V, L63P, I66IV, C67W, A71V, I72V, V77I, I84V, I85IL, N88D, L89LV, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.I13V+p.G16A+p.L19LV+p.L33F+p.E34Q+p.K43I+p.M46L+p.G51A+p.I54M+p.L63P+p.I64M+p.C67Y+p.A71V+p.I72M+p.G73A+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, G16A, L19LV, L33F, E34Q, K43I, M46L, G51A, I54M, L63P, I64M, C67Y, A71V, I72M, G73A, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.T12K+p.I13V+p.K20V+p.V32I+p.L33LF+p.E35G+p.M36I+p.N37ND+p.M46I+p.I47V+p.I54M+p.R57K+p.Q58E+p.L63P+p.I64V+p.A71IV+p.G73S+p.I84IV+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12K, I13V, K20V, V32I, L33LF, E35G, M36I, N37ND, M46I, I47V, I54M, R57K, Q58E, L63P, I64V, A71IV, G73S, I84IV, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.L19I+p.K20T+p.V32I+p.E35N+p.M36I+p.M46I+p.G48Q+p.I54L+p.L63P+p.C67E+p.A71V+p.T74S+p.L76V+p.I84V+p.L89V+p.L90M+p.T91S+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19I, K20T, V32I, E35N, M36I, M46I, G48Q, I54L, L63P, C67E, A71V, T74S, L76V, I84V, L89V, L90M, T91S, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.K20R+p.D30N+p.V32I+p.L33F+p.M36I+p.N37D+p.M46I+p.I54L+p.L63P+p.I64L+p.I66V+p.A71T+p.I72T+p.I84V+p.N88D+p.L89M+p.L90M+p.I93L+p.C95F
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20R, D30N, V32I, L33F, M36I, N37D, M46I, I54L, L63P, I64L, I66V, A71T, I72T, I84V, N88D, L89M, L90M, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.G16A+p.L24I+p.V32I+p.L33F+p.E34EF+p.N37ND+p.M46L+p.I54V+p.L63P+p.A71V+p.I72V+p.V77I+p.V82T+p.I84V
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, G16A, L24I, V32I, L33F, E34EF, N37ND, M46L, I54V, L63P, A71V, I72V, V77I, V82T, I84V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LV+p.V11I+p.I13V+p.K20V+p.L24M+p.V32I+p.L33F+p.E35G+p.M36I+p.I54L+p.K55N+p.D60E+p.L63P+p.C67CG+p.A71I+p.I72L+p.G73S+p.P79S+p.I84V+p.L89V+p.L90M+p.T91S+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, V11I, I13V, K20V, L24M, V32I, L33F, E35G, M36I, I54L, K55N, D60E, L63P, C67CG, A71I, I72L, G73S, P79S, I84V, L89V, L90M, T91S, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LFV+p.V11I+p.I13V+p.I15IV+p.K20V+p.L24M+p.V32I+p.L33F+p.E35G+p.M36I+p.I54L+p.K55N+p.Q58QE+p.D60E+p.L63P+p.A71I+p.I72L+p.G73S+p.P79S+p.V82L+p.I84V+p.L89V+p.L90M+p.T91S+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFV, V11I, I13V, I15IV, K20V, L24M, V32I, L33F, E35G, M36I, I54L, K55N, Q58QE, D60E, L63P, A71I, I72L, G73S, P79S, V82L, I84V, L89V, L90M, T91S, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37D+p.R41IK+p.M46I+p.I47V+p.I54V+p.I62V+p.L63P+p.A71V+p.I72V+p.G73T+p.P79S+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, V32I, L33F, E35D, M36I, N37D, R41IK, M46I, I47V, I54V, I62V, L63P, A71V, I72V, G73T, P79S, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.T12P+p.I13V+p.I15V+p.L19P+p.K20T+p.V32I+p.L33F+p.E35G+p.M36I+p.I54V+p.I62V+p.L63P+p.K70T+p.A71I+p.G73S+p.P79A+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, I15V, L19P, K20T, V32I, L33F, E35G, M36I, I54V, I62V, L63P, K70T, A71I, G73S, P79A, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.G16A+p.L19V+p.L33F+p.E34Q+p.K43I+p.M46L+p.G51A+p.I54M+p.L63P+p.I64M+p.A71V+p.I72M+p.G73A+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, G16A, L19V, L33F, E34Q, K43I, M46L, G51A, I54M, L63P, I64M, A71V, I72M, G73A, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11VI+p.I13V+p.K14KR+p.G16A+p.V32I+p.L33F+p.K43T+p.M46L+p.I54L+p.I62V+p.L63P+p.A71V+p.T74P+p.V82VA+p.I84V+p.L90M+p.T91S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, I13V, K14KR, G16A, V32I, L33F, K43T, M46L, I54L, I62V, L63P, A71V, T74P, V82VA, I84V, L90M, T91S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.T12K+p.I13V+p.K20V+p.V32I+p.L33F+p.E35G+p.M36I+p.N37D+p.M46I+p.I47V+p.I54M+p.R57K+p.Q58E+p.L63P+p.I64V+p.I66V+p.A71V+p.G73S+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12K, I13V, K20V, V32I, L33F, E35G, M36I, N37D, M46I, I47V, I54M, R57K, Q58E, L63P, I64V, I66V, A71V, G73S, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.I13V+p.L19Q+p.K20M+p.V32I+p.L33V+p.E35A+p.M36I+p.M46I+p.I47V+p.I54M+p.R57K+p.I62V+p.L63P+p.I64V+p.G73T+p.T74A+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, L19Q, K20M, V32I, L33V, E35A, M36I, M46I, I47V, I54M, R57K, I62V, L63P, I64V, G73T, T74A, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.I13V+p.V32I+p.L33F+p.E34Q+p.N37S+p.K43KT+p.M46L+p.I54L+p.Q61E+p.I62V+p.L63P+p.A71IV+p.T74P+p.V77I+p.I84V+p.N88G+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, V32I, L33F, E34Q, N37S, K43KT, M46L, I54L, Q61E, I62V, L63P, A71IV, T74P, V77I, I84V, N88G, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.T12P+p.I13V+p.K14R+p.V32I+p.L33F+p.N37T+p.K43Q+p.M46I+p.I47V+p.I54L+p.L63P+p.I66F+p.H69Y+p.A71V+p.I72M+p.G73C+p.V77I+p.P79S+p.V82I+p.I84V+p.N88D+p.L89T+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12P, I13V, K14R, V32I, L33F, N37T, K43Q, M46I, I47V, I54L, L63P, I66F, H69Y, A71V, I72M, G73C, V77I, P79S, V82I, I84V, N88D, L89T, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.T12P+p.I13V+p.I15V+p.L19P+p.K20T+p.V32I+p.L33F+p.E35G+p.M36I+p.I54V+p.I62V+p.L63P+p.K70T+p.A71I+p.G73S+p.P79A+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, I15V, L19P, K20T, V32I, L33F, E35G, M36I, I54V, I62V, L63P, K70T, A71I, G73S, P79A, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.I13V+p.K14KE+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37S+p.R41K+p.K43T+p.M46I+p.I47V+p.F53L+p.I54L+p.K55R+p.R57G+p.D60E+p.I62V+p.L63P+p.K70KE+p.A71V+p.G73C+p.V82I+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, K14KE, K20R, V32I, L33F, E35D, M36I, N37S, R41K, K43T, M46I, I47V, F53L, I54L, K55R, R57G, D60E, I62V, L63P, K70KE, A71V, G73C, V82I, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V32I+p.L33F+p.M36L+p.N37S+p.R41RK+p.M46I+p.I54L+p.K55R+p.R57K+p.I62V+p.L63P+p.I64V+p.I66V+p.G73I+p.I84V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V32I, L33F, M36L, N37S, R41RK, M46I, I54L, K55R, R57K, I62V, L63P, I64V, I66V, G73I, I84V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.I15V+p.K20T+p.V32I+p.L33F+p.E35EK+p.I47V+p.R57G+p.L63P+p.I66F+p.A71V+p.G73S+p.V77I+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, K20T, V32I, L33F, E35EK, I47V, R57G, L63P, I66F, A71V, G73S, V77I, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.T12S+p.I13V+p.K14R+p.L19P+p.K20V+p.V32I+p.E34D+p.E35N+p.M36I+p.K43T+p.M46L+p.I47V+p.I54M+p.R57G+p.I62V+p.L63P+p.A71V+p.G73D+p.T74S+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12S, I13V, K14R, L19P, K20V, V32I, E34D, E35N, M36I, K43T, M46L, I47V, I54M, R57G, I62V, L63P, A71V, G73D, T74S, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11I+p.T12P+p.I13V+p.L19Q+p.K20M+p.V32I+p.E35EG+p.M36IT+p.K43T+p.M46I+p.I47V+p.I54M+p.K55R+p.R57G+p.L63P+p.C67CY+p.H69Q+p.A71I+p.V82A+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, L19Q, K20M, V32I, E35EG, M36IT, K43T, M46I, I47V, I54M, K55R, R57G, L63P, C67CY, H69Q, A71I, V82A, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.V11VI+p.I13V+p.G16A+p.K20T+p.L33LEQ+p.E35EG+p.M46I+p.K55KR+p.R57K+p.Q61H+p.L63P+p.A71V+p.G73S+p.L76V+p.V77VI+p.I84V+p.L89V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11VI, I13V, G16A, K20T, L33LEQ, E35EG, M46I, K55KR, R57K, Q61H, L63P, A71V, G73S, L76V, V77VI, I84V, L89V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.V11I+p.G16GE+p.V32I+p.L33F+p.K43R+p.M46L+p.I54M+p.R57K+p.L63P+p.K70T+p.A71V+p.G73S+p.V77I+p.I84V+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, V11I, G16GE, V32I, L33F, K43R, M46L, I54M, R57K, L63P, K70T, A71V, G73S, V77I, I84V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.V11I+p.I13V+p.K14R+p.I15V+p.K20T+p.V32I+p.L33F+p.M36I+p.R41K+p.M46L+p.I54L+p.R57K+p.D60E+p.L63P+p.G68E+p.K70T+p.A71I+p.I72M+p.G73S+p.I84V+p.L89V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, V11I, I13V, K14R, I15V, K20T, V32I, L33F, M36I, R41K, M46L, I54L, R57K, D60E, L63P, G68E, K70T, A71I, I72M, G73S, I84V, L89V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11L+p.K20R+p.V32I+p.L33F+p.E34S+p.E35D+p.M36V+p.N37S+p.M46I+p.I47V+p.I54M+p.R57K+p.Q58E+p.I62V+p.L63P+p.A71I+p.V77T+p.V82I+p.I84V+p.I85V+p.L89M+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, K20R, V32I, L33F, E34S, E35D, M36V, N37S, M46I, I47V, I54M, R57K, Q58E, I62V, L63P, A71I, V77T, V82I, I84V, I85V, L89M, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.V11I+p.I13V+p.G16A+p.V32I+p.L33F+p.M36IL+p.K43T+p.M46L+p.F53L+p.I54L+p.K55R+p.R57G+p.I62V+p.L63P+p.A71V+p.I72R+p.G73S+p.T74P+p.V82I+p.I84V+p.L89V+p.L90M+p.T91S+p.G94S
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, G16A, V32I, L33F, M36IL, K43T, M46L, F53L, I54L, K55R, R57G, I62V, L63P, A71V, I72R, G73S, T74P, V82I, I84V, L89V, L90M, T91S, G94S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.L19V+p.K20R+p.V32I+p.L33F+p.E35D+p.M36L+p.N37D+p.M46I+p.I54M+p.R57K+p.I62V+p.L63P+p.I66T+p.A71I+p.I72R+p.G73C+p.V77I+p.I84V+p.L89V+p.L90M
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, L19V, K20R, V32I, L33F, E35D, M36L, N37D, M46I, I54M, R57K, I62V, L63P, I66T, A71I, I72R, G73C, V77I, I84V, L89V, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10I+p.E34Q+p.G48V+p.I54S+p.I62V+p.L63P+p.A71V+p.T74S+p.V77I+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E34Q, G48V, I54S, I62V, L63P, A71V, T74S, V77I, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10I+p.T12TK+p.E35D+p.M36MI+p.M46I+p.I54V+p.I62V+p.L63P+p.I64IV+p.G73GC+p.T74S+p.V82A+p.L90M+p.I93L+p.C95F
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TK, E35D, M36MI, M46I, I54V, I62V, L63P, I64IV, G73GC, T74S, V82A, L90M, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10LI+p.I15V+p.G16GE+p.K20R+p.E35D+p.M36I+p.R41K+p.I54IV+p.R57K+p.Q61N+p.L63LH+p.I64IM+p.K70KR+p.L89M+p.L90LM
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I15V, G16GE, K20R, E35D, M36I, R41K, I54IV, R57K, Q61N, L63LH, I64IM, K70KR, L89M, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10I+p.L33LF+p.E34Q+p.M46MIV+p.G48V+p.I50V+p.I54S+p.I62V+p.L63P+p.A71V+p.I72V+p.T74S+p.V77I+p.V82A+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33LF, E34Q, M46MIV, G48V, I50V, I54S, I62V, L63P, A71V, I72V, T74S, V77I, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10I+p.V32I+p.M46I+p.I47A+p.I62V+p.L63P+p.V77I+p.V82I+p.Q92K+p.I93L+p.C95F
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V32I, M46I, I47A, I62V, L63P, V77I, V82I, Q92K, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.G17D+p.L19W+p.K20I+p.M36I+p.M46I+p.I47V+p.I54V+p.I62V+p.L63P+p.A71V+p.I72N+p.G73T+p.I84V+p.I85V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, G17D, L19W, K20I, M36I, M46I, I47V, I54V, I62V, L63P, A71V, I72N, G73T, I84V, I85V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10V+p.I15V+p.G16E+p.K20R+p.E35D+p.M36I+p.R41K+p.M46I+p.I50V+p.I54V+p.K55R+p.R57K+p.Q61N+p.I64IL+p.A71V+p.I72R+p.V82A+p.L89I+p.L90M+p.Q92K
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, G16E, K20R, E35D, M36I, R41K, M46I, I50V, I54V, K55R, R57K, Q61N, I64IL, A71V, I72R, V82A, L89I, L90M, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10I+p.L33F+p.M46I+p.I54V+p.L63P+p.A71V+p.T74P+p.I84V+p.L90M+p.I93L
• Resistant Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, M46I, I54V, L63P, A71V, T74P, I84V, L90M, I93L.

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: HIV2 Protease (HIV2 PR) [10]

• Molecule Alteration: Missense mutation; p.I32V+p.V47I+p.M76L+p.I82V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: HEK293T/17 cells; Kidney; Homo sapiens (Human); CVCL_1926
• Experiment for Molecule Alteration: Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; A single-cycle assay
• Mechanism Description: Single amino acid replacements I32V, V47I, and M76L increased the susceptibility of HIV-2 to multiple PI, but no single change conferred class-wide sensitivity. In contrast, clone PRdeta4 showed PI susceptibility equivalent to or greater than that of HIV-1 for all PI.

Key Molecule: HIV2 Protease (HIV2 PR) [10]

• Molecule Alteration: Missense mutation; p.I82V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: HEK293T/17 cells; Kidney; Homo sapiens (Human); CVCL_1926
• Experiment for Molecule Alteration: Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; A single-cycle assay
• Mechanism Description: Single amino acid replacements I32V, V47I, and M76L increased the susceptibility of HIV-2 to multiple PI, but no single change conferred class-wide sensitivity. In contrast, clone PRdeta4 showed PI susceptibility equivalent to or greater than that of HIV-1 for all PI.

Key Molecule: HIV2 Protease (HIV2 PR) [10]

• Molecule Alteration: Missense mutation; p.M76L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: HEK293T/17 cells; Kidney; Homo sapiens (Human); CVCL_1926
• Experiment for Molecule Alteration: Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; A single-cycle assay
• Mechanism Description: Single amino acid replacements I32V, V47I, and M76L increased the susceptibility of HIV-2 to multiple PI, but no single change conferred class-wide sensitivity. In contrast, clone PRdeta4 showed PI susceptibility equivalent to or greater than that of HIV-1 for all PI.

Key Molecule: HIV2 Protease (HIV2 PR) [10]

• Molecule Alteration: Missense mutation; p.V47I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: HEK293T/17 cells; Kidney; Homo sapiens (Human); CVCL_1926
• Experiment for Molecule Alteration: Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; A single-cycle assay
• Mechanism Description: Single amino acid replacements I32V, V47I, and M76L increased the susceptibility of HIV-2 to multiple PI, but no single change conferred class-wide sensitivity. In contrast, clone PRdeta4 showed PI susceptibility equivalent to or greater than that of HIV-1 for all PI.

Key Molecule: HIV2 Protease (HIV2 PR) [10]

• Molecule Alteration: Missense mutation; p.I32V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: HEK293T/17 cells; Kidney; Homo sapiens (Human); CVCL_1926
• Experiment for Molecule Alteration: Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; A single-cycle assay
• Mechanism Description: Single amino acid replacements I32V, V47I, and M76L increased the susceptibility of HIV-2 to multiple PI, but no single change conferred class-wide sensitivity. In contrast, clone PRdeta4 showed PI susceptibility equivalent to or greater than that of HIV-1 for all PI.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.G16E+p.M36MI+p.P39S+p.R41K+p.R57G+p.L63T+p.A71V+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.R57G+p.L63AT+p.E65D+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.K14R+p.Q18E+p.E35D+p.M36I+p.R57G+p.I62V+p.L63P+p.I72V+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.I13V+p.R57G+p.L63D+p.I64V+p.E65D+p.K70R+p.I72T
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.T12TA+p.I13V+p.G17E+p.K20I+p.M36I+p.R41K+p.R57G+p.L63P+p.H69K+p.K70KR+p.I72L+p.L89I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.T12TP+p.I13IV+p.K14KR+p.N37S+p.R57K+p.L63P+p.I64V+p.C67X
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.E35D+p.N37S+p.R57K+p.I62IV+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.N37T+p.R57K+p.I62V+p.L63ST+p.A71T+p.I72V+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.N37D+p.R57K+p.D60DE+p.I62V+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.T12PS+p.I13V+p.L19LI+p.N37A+p.R57G+p.L63P+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.E35D+p.N37S+p.R41K+p.R57G+p.I62IV+p.L63A+p.I72IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.R57G+p.L63P+p.I72E+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.I13V+p.I15L+p.L33V+p.N37S+p.R41K+p.K45KR+p.R57K+p.L63X+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.T12S+p.L19I+p.E35D+p.R57K+p.L63P+p.H69Q+p.A71AT
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [2]

• Molecule Alteration: Missense mutation; p.T12P+p.N37S+p.R57G+p.L63A+p.I72V+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: GeneSeq assay; PhenoSense GT assay
• Experiment for Drug Resistance: Viral load assay
• Mechanism Description: Amino acid changes in IN may contribute to drug resistance or sensitivity.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K45R+p.I50L+p.I62V+p.L63P+p.A71IT+p.I72V+p.G73GS+p.V77I+p.V82A+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K45R, I50L, I62V, L63P, A71IT, I72V, G73GS, V77I, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.I13V+p.K14KR+p.K20KT+p.E35D+p.M36I+p.R41KN+p.H69K+p.V77VI+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13V, K14KR, K20KT, E35D, M36I, R41KN, H69K, V77VI, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36MI+p.K45R+p.R57G+p.I62M+p.L63P+p.A71T+p.I72E+p.I93IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, K45R, R57G, I62M, L63P, A71T, I72E, I93IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.I72T+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I72T, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.N37NS+p.L63P+p.I72E
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37NS, L63P, I72E.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.M36MI+p.L63A+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M36MI, L63A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35ED+p.M36MI+p.N37X+p.R41RK+p.I62IL+p.L63LP+p.A71AV+p.V77I+p.N83ND+p.C95CR
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35ED, M36MI, N37X, R41RK, I62IL, L63LP, A71AV, V77I, N83ND, C95CR.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.Q61E+p.I62V+p.L63T+p.E65D+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q61E, I62V, L63T, E65D, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I3M+p.K14R+p.R41K+p.R57G+p.L63P+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3M, K14R, R41K, R57G, L63P, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.R41RK+p.R57G+p.Q61H+p.I64IV+p.V77L+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R41RK, R57G, Q61H, I64IV, V77L, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K14KR+p.E35D+p.R57K+p.L63P+p.I64V+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14KR, E35D, R57K, L63P, I64V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.R57G+p.L63P+p.I64L+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R57G, L63P, I64L, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L23I+p.R57K+p.L63P+p.H69Y+p.A71V+p.N88S+p.Q92R+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L23I, R57K, L63P, H69Y, A71V, N88S, Q92R, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19I+p.M36I+p.N37D+p.R41K+p.R57G+p.Q61E+p.I64V+p.E65ED+p.C67CW
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, M36I, N37D, R41K, R57G, Q61E, I64V, E65ED, C67CW.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.K14KR+p.M36I+p.R57K+p.I62V+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, K14KR, M36I, R57K, I62V, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.I13V+p.D30N+p.L63P+p.K70R+p.A71T+p.V77I+p.N88D
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13V, D30N, L63P, K70R, A71T, V77I, N88D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20KIM+p.R41RK+p.I64V+p.V77IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20KIM, R41RK, I64V, V77IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37NS+p.G48GE+p.Q61E+p.L63S+p.E65D+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37NS, G48GE, Q61E, L63S, E65D, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L19IT+p.G48V+p.I54V+p.I64V+p.V82A+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19IT, G48V, I54V, I64V, V82A, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.K70T+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, K70T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36I+p.I62V+p.L63A+p.I72IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, I62V, L63A, I72IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37D+p.D60E+p.I62V+p.L63P+p.G68E+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37D, D60E, I62V, L63P, G68E, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.N37D+p.R41K+p.I62V+p.L63A+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, N37D, R41K, I62V, L63A, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.I15V+p.G16A+p.E35D+p.N37D+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I15V, G16A, E35D, N37D, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12TK+p.K14R+p.L23I+p.L33LV+p.E35D+p.M36V+p.N37H+p.R41K+p.M46I+p.I50L+p.R57K+p.L63P+p.I64V+p.K70R+p.V82A+p.I85V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TK, K14R, L23I, L33LV, E35D, M36V, N37H, R41K, M46I, I50L, R57K, L63P, I64V, K70R, V82A, I85V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20I+p.L33V+p.M46L+p.L63P+p.A71T+p.I72V+p.T74K+p.I85V+p.N88D+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, L33V, M46L, L63P, A71T, I72V, T74K, I85V, N88D, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.N37D+p.G48V+p.F53L+p.I54V+p.L63P+p.A71T+p.V77I+p.V82A+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37D, G48V, F53L, I54V, L63P, A71T, V77I, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L38I+p.K43R+p.I62V+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L38I, K43R, I62V, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.L63Q
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63Q.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14KR+p.I15IV+p.L19T+p.R41K+p.I64IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, I15IV, L19T, R41K, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K45R+p.I62IV+p.L63S+p.I64M+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K45R, I62IV, L63S, I64M, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12Q+p.I13V+p.K20KR+p.L63Q+p.I64V+p.I72IMV+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12Q, I13V, K20KR, L63Q, I64V, I72IMV, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.E35D+p.N37D+p.M46I+p.K55KR+p.L63P+p.A71V+p.G73S+p.V77I+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, E35D, N37D, M46I, K55KR, L63P, A71V, G73S, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.D30N+p.R41K+p.L63P+p.I64V+p.V75I+p.V77I+p.N88D+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, D30N, R41K, L63P, I64V, V75I, V77I, N88D, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R41RK+p.I62IV+p.L63A+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41RK, I62IV, L63A, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35D+p.R57G+p.L63LP
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, R57G, L63LP.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R41K+p.R57G+p.L63P+p.T74TA+p.V77I+p.L90LM+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, R57G, L63P, T74TA, V77I, L90LM, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15IV+p.N37X+p.L38IM+p.R41RK+p.R57G+p.I62V+p.I64IV+p.H69HY+p.I72IMV+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, N37X, L38IM, R41RK, R57G, I62V, I64IV, H69HY, I72IMV, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12S+p.L19I+p.N37S+p.R57G+p.L63A+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, L19I, N37S, R57G, L63A, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I15V+p.P39Q+p.R57K+p.L63P+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, P39Q, R57K, L63P, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10H+p.I13IV+p.Q18H+p.L19IM+p.K20T+p.R41K+p.M46I+p.D60E+p.L63P+p.A71I+p.V77I+p.I93L+p.C95CY
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10H, I13IV, Q18H, L19IM, K20T, R41K, M46I, D60E, L63P, A71I, V77I, I93L, C95CY.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.G17E+p.D60E+p.L63P+p.I64V+p.K70R+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G17E, D60E, L63P, I64V, K70R, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15IV+p.I64IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63T+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63T, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36MI+p.R41RK+p.I62IV+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, R41RK, I62IV, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.P39Q+p.I62V+p.L63P+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, P39Q, I62V, L63P, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L24I+p.R41K+p.M46I+p.I54V+p.I64V+p.V77I+p.V82A
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, R41K, M46I, I54V, I64V, V77I, V82A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.L33LF+p.M36ML+p.N37ND+p.K45KN+p.I50IL+p.I54IV+p.L63LP+p.I64V+p.I72IT+p.V82VA
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L33LF, M36ML, N37ND, K45KN, I50IL, I54IV, L63LP, I64V, I72IT, V82VA.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.D30N+p.K43T+p.M46I+p.D60E+p.Q61E+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, D30N, K43T, M46I, D60E, Q61E, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19Q+p.M36I+p.N37C+p.I62V+p.L63P+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, M36I, N37C, I62V, L63P, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.L19I+p.E35D+p.N37D+p.D60E+p.I62V+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, L19I, E35D, N37D, D60E, I62V, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.N37ST+p.I62IV+p.L63P+p.K70R+p.A71AT+p.I72IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37ST, I62IV, L63P, K70R, A71AT, I72IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12I+p.G16E+p.P39S+p.L63T+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12I, G16E, P39S, L63T, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.K20KIM+p.M36MI+p.N37D+p.R41K+p.D60E+p.I62V+p.L63P+p.I64IL+p.H69Y+p.I72E
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, K20KIM, M36MI, N37D, R41K, D60E, I62V, L63P, I64IL, H69Y, I72E.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37S+p.L63T+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, L63T, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.L19V+p.M36MI+p.R41K+p.Q61N+p.I64V+p.E65D+p.I72E
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L19V, M36MI, R41K, Q61N, I64V, E65D, I72E.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.I15IV+p.K20X+p.D60E+p.Q61E+p.L63P+p.I64M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15IV, K20X, D60E, Q61E, L63P, I64M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.I13V+p.L63P+p.I64V+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I13V, L63P, I64V, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19I+p.L63S+p.E65D+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, L63S, E65D, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15IV+p.Q18H+p.E21EG+p.N37S+p.K43KR+p.R57K+p.L63P+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, Q18H, E21EG, N37S, K43KR, R57K, L63P, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.L19Q+p.R41K+p.I54V+p.D60E+p.I62V+p.L63PT+p.A71V+p.V82A+p.I93M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19Q, R41K, I54V, D60E, I62V, L63PT, A71V, V82A, I93M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.I13IV+p.I15V+p.E35ED+p.N37C+p.R41RK+p.I62IL+p.L63LP+p.A71AV+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13IV, I15V, E35ED, N37C, R41RK, I62IL, L63LP, A71AV, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12S+p.K14R+p.R41K+p.I62V+p.L63P+p.I64M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, K14R, R41K, I62V, L63P, I64M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.M36MI+p.N37D+p.L63X+p.H69Y
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36MI, N37D, L63X, H69Y.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I15V+p.K20R+p.N37S+p.L63P+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20R, N37S, L63P, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37E+p.L63P+p.K70T+p.I72R
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37E, L63P, K70T, I72R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.M36MI+p.N37D+p.R57G+p.L63X+p.H69Y
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36MI, N37D, R57G, L63X, H69Y.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.R57G+p.I64V+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, I64V, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37S+p.R41K+p.R57G+p.D60DE+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R41K, R57G, D60DE, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.L63P+p.I64L+p.A71T+p.I72T+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63P, I64L, A71T, I72T, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35D+p.P39PS+p.R57G
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, P39PS, R57G.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.Q18E+p.R57G+p.I62IV+p.L63S+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q18E, R57G, I62IV, L63S, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.L19I+p.M36I+p.N37T+p.R41K+p.K45KR+p.R57G+p.I62M+p.L63P+p.I64M+p.A71V+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, L19I, M36I, N37T, R41K, K45KR, R57G, I62M, L63P, I64M, A71V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19Q+p.R57G+p.D60DE+p.L63LP+p.I64V+p.K70KR
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, R57G, D60DE, L63LP, I64V, K70KR.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.M36I+p.R57G+p.L63P+p.A71T+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, M36I, R57G, L63P, A71T, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.N37D+p.R57G+p.L63S+p.H69R
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37D, R57G, L63S, H69R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35D+p.M36T+p.N37E+p.R57G+p.I62V+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, M36T, N37E, R57G, I62V, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LV+p.T12P+p.I13V+p.K14KR+p.N37D+p.R57G+p.L63Q+p.I64V+p.E65D
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, T12P, I13V, K14KR, N37D, R57G, L63Q, I64V, E65D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.T12PS+p.I15IV+p.K20KM+p.M36MI+p.N37ND+p.K45KR+p.I54IV+p.R57G+p.I62IV+p.L63P+p.A71AT+p.G73X+p.V82X+p.I85IV+p.L90LM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12PS, I15IV, K20KM, M36MI, N37ND, K45KR, I54IV, R57G, I62IV, L63P, A71AT, G73X, V82X, I85IV, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.R57G+p.L63P+p.I64L+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R57G, L63P, I64L, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.N37Y+p.R41K+p.R57K+p.L63LP+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37Y, R41K, R57K, L63LP, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L33LV+p.N37C+p.P39PS+p.L63P+p.H69HY
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33LV, N37C, P39PS, L63P, H69HY.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.R57RK+p.L63P+p.I64IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57RK, L63P, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.N37S+p.R41K+p.I64IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, N37S, R41K, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LF+p.I13V+p.I15V+p.G16GA+p.K20X+p.M36MI+p.N37T+p.I54IV+p.R57K+p.L63LP+p.I64V+p.K70R+p.V82VA+p.L90LM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, I13V, I15V, G16GA, K20X, M36MI, N37T, I54IV, R57K, L63LP, I64V, K70R, V82VA, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.I13V+p.L33LF+p.M36MI+p.N37NS+p.R41K+p.Q58QE+p.Q61N+p.L63LP+p.V82VA+p.N88NS
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13V, L33LF, M36MI, N37NS, R41K, Q58QE, Q61N, L63LP, V82VA, N88NS.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R41RK+p.H69HY
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41RK, H69HY.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.N37T+p.I62V+p.L63HQ+p.I72IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, N37T, I62V, L63HQ, I72IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15IV+p.K43KR+p.I62V+p.L63P+p.I72IV+p.V77I+p.L90LM+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, K43KR, I62V, L63P, I72IV, V77I, L90LM, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.I15V+p.R41K+p.I62V+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I15V, R41K, I62V, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37Y+p.R41K+p.R57K+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37Y, R41K, R57K, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19LI+p.N37S
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19LI, N37S.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.G16GE+p.L19V+p.K20I+p.L63P+p.K70R+p.A71T
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, G16GE, L19V, K20I, L63P, K70R, A71T.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20T+p.D60E+p.L63P+p.C67D+p.A71V+p.V77I+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20T, D60E, L63P, C67D, A71V, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L23LI+p.V32VI+p.I50IL+p.I62V+p.L63P+p.A71AV+p.G73CS+p.V77I+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L23LI, V32VI, I50IL, I62V, L63P, A71AV, G73CS, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.K14R+p.G16E+p.L19I+p.K20IT+p.E35D+p.M36I+p.P39T+p.F53FL+p.I54V+p.I62V+p.I66F+p.H69K+p.A71AV+p.T74S+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K14R, G16E, L19I, K20IT, E35D, M36I, P39T, F53FL, I54V, I62V, I66F, H69K, A71AV, T74S, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I64V+p.I72V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I64V, I72V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I3L+p.L10I+p.R41K+p.R57K+p.L63Q+p.I64V+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3L, L10I, R41K, R57K, L63Q, I64V, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R41K+p.L63P+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, L63P, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36I+p.I62V+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, I62V, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.L19IT+p.M36MIL+p.I62V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L19IT, M36MIL, I62V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.I64L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I64L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.N37S+p.R41K+p.I64V+p.Q92K
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, N37S, R41K, I64V, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20R+p.E35D+p.M36I+p.I62V+p.L63P+p.I64L+p.T74S+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, E35D, M36I, I62V, L63P, I64L, T74S, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.NULL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.M36I+p.R41K
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, R41K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14KR+p.E35D+p.N37NS+p.R41K
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, E35D, N37NS, R41K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.I13V+p.K14R+p.E35D+p.N37S+p.Q61E+p.L63P+p.I64IV+p.A71AT+p.I72IV+p.I93IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, I13V, K14R, E35D, N37S, Q61E, L63P, I64IV, A71AT, I72IV, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R8RQ+p.T12S+p.I15IV+p.L19I+p.N37S+p.I62IV+p.L63X+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R8RQ, T12S, I15IV, L19I, N37S, I62IV, L63X, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.I15V+p.G16E+p.K20KT+p.M36I+p.P39S+p.D60E+p.I62V+p.L63P+p.I72V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, I15V, G16E, K20KT, M36I, P39S, D60E, I62V, L63P, I72V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.N37D+p.K70R+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, N37D, K70R, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I15V+p.K20R+p.N37NS+p.L63P+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20R, N37NS, L63P, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R41K+p.D60E+p.I64V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, D60E, I64V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36MI+p.N37S+p.R41K+p.L63LP+p.I64IV+p.I72IV+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, N37S, R41K, L63LP, I64IV, I72IV, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.K20X+p.M36I+p.R41RK+p.I62V+p.L63P+p.A71T+p.I72T+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20X, M36I, R41RK, I62V, L63P, A71T, I72T, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I64V+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I64V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.R57G+p.I62V+p.L63Q+p.V77VI+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, R57G, I62V, L63Q, V77VI, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.R41K+p.K55R+p.R57G+p.L63H+p.I64V+p.E65D+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, R41K, K55R, R57G, L63H, I64V, E65D, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.T12TP+p.K14KR+p.N37X+p.R41RK+p.R57G+p.I62V+p.L63T+p.I64L+p.C67S+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12TP, K14KR, N37X, R41RK, R57G, I62V, L63T, I64L, C67S, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IA+p.I15IV+p.N37NS+p.R57G+p.I72IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IA, I15IV, N37NS, R57G, I72IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.W6P+p.R41K+p.R57G+p.I62V+p.C67S+p.H69Y+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6P, R41K, R57G, I62V, C67S, H69Y, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.P39PT+p.R57G+p.L63P+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, P39PT, R57G, L63P, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.R57G+p.D60E+p.I62IV+p.L63A+p.I64ILM+p.A71AT+p.I72IV+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, D60E, I62IV, L63A, I64ILM, A71AT, I72IV, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35D+p.R57G+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, R57G, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.N37A+p.R41K+p.R57G+p.L63T+p.E65D+p.I72T+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, N37A, R41K, R57G, L63T, E65D, I72T, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K20R+p.E35D+p.P39PS+p.R57G+p.L63LP+p.A71V+p.I72IV+p.V77VIM+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, E35D, P39PS, R57G, L63LP, A71V, I72IV, V77VIM, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37S+p.R57G+p.Q61E+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R57G, Q61E, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35D+p.R57G
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, R57G.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I15V+p.L19I+p.E35D+p.N37D+p.R57G+p.L63P+p.I64L+p.H69Y
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, L19I, E35D, N37D, R57G, L63P, I64L, H69Y.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.R57G+p.D60E+p.I62IV+p.L63A+p.I64ILM+p.A71AT+p.I72IV+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, D60E, I62IV, L63A, I64ILM, A71AT, I72IV, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.N37E+p.R57G+p.I62V+p.L63P+p.A71T+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, N37E, R57G, I62V, L63P, A71T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35X+p.N37X+p.L38LM+p.R41RK+p.R57G+p.I62IV+p.L63HP+p.A71AV+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35X, N37X, L38LM, R41RK, R57G, I62IV, L63HP, A71AV, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.R57G+p.L63P+p.I72V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57G, L63P, I72V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12I+p.N37D+p.K45KR+p.R57G+p.L63Q+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12I, N37D, K45KR, R57G, L63Q, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12V+p.G17D+p.K20M+p.E35G+p.M36I+p.G48V+p.F53L+p.I54V+p.R57K+p.I62V+p.L63P+p.A71V+p.V82A+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12V, G17D, K20M, E35G, M36I, G48V, F53L, I54V, R57K, I62V, L63P, A71V, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.M36I+p.K43T+p.G48V+p.I54V+p.I62V+p.I64V+p.T74S+p.V82A
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, M36I, K43T, G48V, I54V, I62V, I64V, T74S, V82A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.N37S+p.M46I+p.L63P+p.A71T+p.V77I+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, N37S, M46I, L63P, A71T, V77I, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.L63P+p.E65D
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63P, E65D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IM+p.I15IV+p.L19LI+p.R41K+p.Q61QR+p.L63LP+p.I72V+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IM, I15IV, L19LI, R41K, Q61QR, L63LP, I72V, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.Q18H+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, Q18H, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12TS+p.I13V+p.K14KR+p.L19X+p.N37ND+p.L63P+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TS, I13V, K14KR, L19X, N37ND, L63P, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.N37T+p.L63P+p.T74TA
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37T, L63P, T74TA.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36MI+p.Q58E+p.I62IV+p.L63X+p.I64IV+p.K70R+p.V77VI+p.L90LM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, Q58E, I62IV, L63X, I64IV, K70R, V77VI, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12AS+p.I15IV+p.L19LI+p.M36I+p.N37D+p.I62V+p.L63P+p.I72IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12AS, I15IV, L19LI, M36I, N37D, I62V, L63P, I72IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14E+p.L19I+p.L33V+p.N37C+p.R41K+p.K45KR+p.I62V+p.I64V+p.E65K+p.H69Y+p.A71AV+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14E, L19I, L33V, N37C, R41K, K45KR, I62V, I64V, E65K, H69Y, A71AV, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.I64L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I64L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L33I+p.I62V+p.L63T+p.I64L+p.A71V+p.I72T+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33I, I62V, L63T, I64L, A71V, I72T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.H69Q+p.K70R+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, H69Q, K70R, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.N37T+p.L63E+p.I64V+p.E65D+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37T, L63E, I64V, E65D, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.L19LQ+p.K20I+p.E34Q+p.E35D+p.M36V+p.N37E+p.M46I+p.F53L+p.I54V+p.R57K+p.L63P+p.A71T+p.V77I+p.V82A+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19LQ, K20I, E34Q, E35D, M36V, N37E, M46I, F53L, I54V, R57K, L63P, A71T, V77I, V82A, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15IV+p.L23LI+p.D29DG+p.I50IL+p.K55KR+p.L63P+p.I72E+p.G73GS+p.I84IV+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IV, L23LI, D29DG, I50IL, K55KR, L63P, I72E, G73GS, I84IV, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14KR+p.L19I+p.D60DE+p.L63X+p.H69HY+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, L19I, D60DE, L63X, H69HY, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.D30N+p.L33F+p.I62V+p.L63P+p.I64L+p.A71AV+p.V77I+p.N88D+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D30N, L33F, I62V, L63P, I64L, A71AV, V77I, N88D, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10R+p.V32I+p.N37H+p.R41K+p.M46I+p.I47V+p.I50L+p.L63P+p.A71I+p.I72V+p.V77I+p.V82T+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10R, V32I, N37H, R41K, M46I, I47V, I50L, L63P, A71I, I72V, V77I, V82T, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12E+p.K20I+p.E35D+p.I62V+p.L63P+p.A71V+p.G73S+p.V77I+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12E, K20I, E35D, I62V, L63P, A71V, G73S, V77I, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10IV+p.I13IV+p.K20R+p.M36I+p.I54V+p.I62V+p.L63P+p.I64IL+p.A71V+p.I72IV+p.V82AT+p.L90LM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13IV, K20R, M36I, I54V, I62V, L63P, I64IL, A71V, I72IV, V82AT, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.I15V+p.R41K+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, I15V, R41K, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.R41K+p.L63P+p.H69R+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R41K, L63P, H69R, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.N37NT+p.R57K+p.Q58QE+p.D60E+p.Q61QE+p.L63P+p.I64IL+p.V77VI+p.N88NS
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, N37NT, R57K, Q58QE, D60E, Q61QE, L63P, I64IL, V77VI, N88NS.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I15V+p.K20R+p.M36I+p.R41K+p.H69K+p.L89M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20R, M36I, R41K, H69K, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K20I+p.E35DN+p.M36V+p.I62V+p.L63P+p.T74TS+p.V75VI+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20I, E35DN, M36V, I62V, L63P, T74TS, V75VI, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15IL+p.K43KR+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IL, K43KR, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12N+p.L19I+p.L63P+p.C67D+p.I72MT+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, L19I, L63P, C67D, I72MT, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37NS+p.R41RK
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37NS, R41RK.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K20KI+p.L63A+p.A71AV+p.V77I+p.L90LM+p.I93IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KI, L63A, A71AV, V77I, L90LM, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12N+p.L63P+p.H69Q+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, L63P, H69Q, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.L63A+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63A, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I3IV+p.I13IV+p.I64V+p.C67CG+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3IV, I13IV, I64V, C67CG, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LV+p.K14KR+p.I64IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, K14KR, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LF+p.K14KE+p.E35D+p.N37ND+p.R57RK+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, K14KE, E35D, N37ND, R57RK, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.M36I+p.L63C
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, L63C.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.M46I+p.I62V+p.I64V+p.K70R+p.T74A+p.V77I+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, M46I, I62V, I64V, K70R, T74A, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LR+p.Q18H+p.L19LI+p.L33LF+p.M46ML+p.I54IL+p.I62V+p.L63P+p.A71AV+p.I72ILM+p.G73X+p.V77I+p.I84IV+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LR, Q18H, L19LI, L33LF, M46ML, I54IL, I62V, L63P, A71AV, I72ILM, G73X, V77I, I84IV, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19Q+p.E35D+p.M36MI+p.N37NS+p.R41K+p.K55R+p.R57RK+p.L63P+p.V75VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, E35D, M36MI, N37NS, R41K, K55R, R57RK, L63P, V75VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.N37T+p.R41K+p.K43KR+p.L63Q
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, N37T, R41K, K43KR, L63Q.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.L19I+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, L19I, K20I, E35Q, M36I, R41K, R57K, C67E, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.L19I+p.E35D+p.N37X+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L19I, E35D, N37X, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.R41K+p.L63P+p.I64L+p.A71AV+p.I84IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R41K, L63P, I64L, A71AV, I84IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35ED+p.N37C+p.R41RK+p.L63LP+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35ED, N37C, R41RK, L63LP, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.E35D+p.N37T+p.L63P+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, E35D, N37T, L63P, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.Q61E+p.I62V+p.L63P+p.C67Y+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, Q61E, I62V, L63P, C67Y, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.L63H+p.V77I+p.L89I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63H, V77I, L89I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.N37D+p.G48GV+p.I54IT+p.R57G+p.L63LP+p.H69HR+p.A71X+p.V77VI+p.V82VA+p.I93IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, N37D, G48GV, I54IT, R57G, L63LP, H69HR, A71X, V77VI, V82VA, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12I+p.I15V+p.E35D+p.N37D+p.R57RK+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12I, I15V, E35D, N37D, R57RK, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36I+p.R57K+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R57K, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.E35D+p.N37S+p.R57G+p.L63P+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, N37S, R57G, L63P, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12A+p.I15V+p.G16E+p.P39S+p.R57G+p.L63P+p.A71T+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I15V, G16E, P39S, R57G, L63P, A71T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37S+p.R41RK+p.R57G+p.L63A+p.Q92QK
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R41RK, R57G, L63A, Q92QK.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.R57G+p.L63P+p.I64V+p.I72IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57G, L63P, I64V, I72IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12TP+p.I13V+p.M36I+p.R57G+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TP, I13V, M36I, R57G, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19I+p.E35D+p.R57G+p.L63A
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, E35D, R57G, L63A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.I13V+p.G16GE+p.L24LI+p.D30N+p.L33I+p.E35D+p.M36I+p.N37S+p.K45Q+p.M46MI+p.I54V+p.R57G+p.D60E+p.I62V+p.L63S+p.I64V+p.I72IM+p.Q92QK
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, G16GE, L24LI, D30N, L33I, E35D, M36I, N37S, K45Q, M46MI, I54V, R57G, D60E, I62V, L63S, I64V, I72IM, Q92QK.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.I15IV+p.Q18QH+p.R57RK+p.I62IV+p.L63P+p.I64IV+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15IV, Q18QH, R57RK, I62IV, L63P, I64IV, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.K43KR+p.R57G+p.L63P+p.V82VI+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, K43KR, R57G, L63P, V82VI, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.K14KR+p.I15V+p.L19I+p.M36I+p.K43R+p.R57K+p.L63P+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14KR, I15V, L19I, M36I, K43R, R57K, L63P, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.L24I+p.L33F+p.M36L+p.K43T+p.M46I+p.I54V+p.D60E+p.I62V+p.L63P+p.A71V+p.T74S+p.V82A+p.N83D+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24I, L33F, M36L, K43T, M46I, I54V, D60E, I62V, L63P, A71V, T74S, V82A, N83D, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K20V+p.F53L+p.L63P+p.A71V+p.G73S+p.V77I+p.I85IV+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20V, F53L, L63P, A71V, G73S, V77I, I85IV, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.R41K+p.I62V+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, R41K, I62V, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LV+p.T12TS+p.K14NS+p.I15IV+p.L19LI+p.N37ND+p.R41RK+p.K45KR+p.D60DE+p.L63LP+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, T12TS, K14NS, I15IV, L19LI, N37ND, R41RK, K45KR, D60DE, L63LP, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19LV+p.Q61E+p.L63LP+p.I64IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19LV, Q61E, L63LP, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.N37D+p.R41RK+p.I64V+p.H69Y
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, N37D, R41RK, I64V, H69Y.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15IV+p.M36I+p.R41K+p.R57RK+p.L63LP+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, M36I, R41K, R57RK, L63LP, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.L19I+p.K20M+p.L24I+p.E35D+p.M36I+p.G48Q+p.F53L+p.I54V+p.L63P+p.K70E+p.A71V+p.I72M+p.G73S+p.V75VI+p.V82A+p.I93IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19I, K20M, L24I, E35D, M36I, G48Q, F53L, I54V, L63P, K70E, A71V, I72M, G73S, V75VI, V82A, I93IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12S+p.I13V+p.K14KR+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I13V, K14KR, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K43KT+p.I54V+p.L63P+p.A71V+p.I72V+p.V82A
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K43KT, I54V, L63P, A71V, I72V, V82A.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.T12S+p.L19Q+p.L23I+p.M46I+p.I54L+p.K55R+p.L63P+p.A71IV+p.G73S+p.V77I+p.V82T+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12S, L19Q, L23I, M46I, I54L, K55R, L63P, A71IV, G73S, V77I, V82T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.E35D+p.P39PQS+p.L63P+p.A71AT+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, P39PQS, L63P, A71AT, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.I62IV+p.L63P+p.A71AV+p.G73GS+p.V77VI+p.I84IV+p.L90LM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, I62IV, L63P, A71AV, G73GS, V77VI, I84IV, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.K14KR+p.N37CS+p.R41RK+p.I64V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, K14KR, N37CS, R41RK, I64V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.L33LV+p.R41RK+p.L63LP+p.I64IV+p.I72IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L33LV, R41RK, L63LP, I64IV, I72IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19I+p.R57K+p.L63S+p.I64V+p.E65D
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, R57K, L63S, I64V, E65D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36MI+p.I62V+p.L63P+p.I64L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, I62V, L63P, I64L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K20KR+p.E35ED+p.M36I+p.N37D+p.R41RK+p.L63P+p.I64L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, E35ED, M36I, N37D, R41RK, L63P, I64L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.R41K+p.L63A+p.I64V+p.K70R
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, R41K, L63A, I64V, K70R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.E35D+p.M36I+p.I62V+p.L63A+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, E35D, M36I, I62V, L63A, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.N37NS+p.R41K+p.L63A+p.I64V+p.H69Y+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, N37NS, R41K, L63A, I64V, H69Y, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.I62V+p.L63P
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, I62V, L63P.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.N37D+p.R57K+p.L63P+p.A71T+p.I72IV+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57K, L63P, A71T, I72IV, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.L63A+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L63A, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.D60E+p.I62V+p.L63A+p.I64L+p.A71T+p.I72V+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, D60E, I62V, L63A, I64L, A71T, I72V, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.M36I+p.G48V+p.I54V+p.I62V+p.L63P+p.T74S+p.V82A+p.C95G
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M36I, G48V, I54V, I62V, L63P, T74S, V82A, C95G.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.L63A+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L63A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.N37D+p.R57G+p.I62V+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57G, I62V, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K20KR+p.E35D+p.M36I+p.R57RK+p.I62V+p.L63APS+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, E35D, M36I, R57RK, I62V, L63APS, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12P+p.K14R+p.E35D+p.N37DE+p.R57G+p.L63P+p.A71T+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14R, E35D, N37DE, R57G, L63P, A71T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19Q+p.K20T+p.D30N+p.L33V+p.R57G+p.A71V+p.N88D
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, K20T, D30N, L33V, R57G, A71V, N88D.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.I15IV+p.M36MI+p.R57G+p.I72IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15IV, M36MI, R57G, I72IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.I62V+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, I62V, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.R57G+p.L63P+p.H69Q
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57G, L63P, H69Q.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I15V+p.M36I+p.N37D+p.R57G+p.L63T+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, M36I, N37D, R57G, L63T, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.K14R+p.E35D+p.M36I+p.N37E+p.R57G+p.L63P+p.A71V+p.V77I+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, E35D, M36I, N37E, R57G, L63P, A71V, V77I, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.N37D+p.R57G+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37D, R57G, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12TA+p.K14KR+p.K20KE+p.E35D+p.R41RK+p.R57G+p.I62V+p.L63P+p.V77VI+p.I93IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TA, K14KR, K20KE, E35D, R41RK, R57G, I62V, L63P, V77VI, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.L63P+p.I64IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63P, I64IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36I+p.R41K+p.R57G+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R41K, R57G, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R41K+p.R57G+p.I62V+p.L63P+p.V77I+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, R57G, I62V, L63P, V77I, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12TS+p.I13V+p.I15IV+p.K20KLM+p.E35D+p.M36I+p.N37D+p.K45R+p.R57G+p.I64V+p.I72IT+p.L90LM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TS, I13V, I15IV, K20KLM, E35D, M36I, N37D, K45R, R57G, I64V, I72IT, L90LM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.R57G+p.L63P+p.I64L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, R57G, L63P, I64L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.G16E+p.K55KR+p.R57G+p.I72IR+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G16E, K55KR, R57G, I72IR, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15IV+p.R41K+p.R57K+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, R41K, R57K, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13V+p.R57G+p.L63P+p.K70R+p.I72IV+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R57G, L63P, K70R, I72IV, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19I+p.M36I+p.N37D+p.R41K+p.R57G+p.Y59H+p.Q61E+p.I62V+p.L63T+p.I64V+p.A71V+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, M36I, N37D, R41K, R57G, Y59H, Q61E, I62V, L63T, I64V, A71V, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.R57G+p.D60E+p.I62IV+p.L63A+p.I64ILM+p.A71AT+p.I72IV+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, D60E, I62IV, L63A, I64ILM, A71AT, I72IV, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.M36I+p.N37D+p.R57K+p.I62IV+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M36I, N37D, R57K, I62IV, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.N37ND+p.R41K+p.R57RK+p.I62IV+p.L63P+p.A71V+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, N37ND, R41K, R57RK, I62IV, L63P, A71V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.V11VI+p.T12TA+p.I13IV+p.L19I+p.K20I+p.D30N+p.E35N+p.M36I+p.N37DE+p.F53FL+p.I54IV+p.Q58QE+p.D60E+p.Q61E+p.L63P+p.A71V+p.I72T+p.N83ND+p.N88D+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, T12TA, I13IV, L19I, K20I, D30N, E35N, M36I, N37DE, F53FL, I54IV, Q58QE, D60E, Q61E, L63P, A71V, I72T, N83ND, N88D, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.Q18L+p.E35D+p.M36I+p.I62IV+p.L63P+p.K70KR
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q18L, E35D, M36I, I62IV, L63P, K70KR.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T12R+p.I15V+p.L19I+p.R41K+p.H69Y
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12R, I15V, L19I, R41K, H69Y.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I13V+p.L33V+p.M36MI+p.R41K+p.I64V+p.R87RK
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, L33V, M36MI, R41K, I64V, R87RK.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.T12R+p.I15V+p.K20T+p.N37D+p.M46I+p.K55KR+p.I62V+p.L63P+p.A71T+p.G73S+p.T74S+p.V77I+p.T80TA+p.V82T+p.I85V+p.L90M+p.I93L+p.C95F
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12R, I15V, K20T, N37D, M46I, K55KR, I62V, L63P, A71T, G73S, T74S, V77I, T80TA, V82T, I85V, L90M, I93L, C95F.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.L33IV+p.M46L+p.I54V+p.D60E+p.L63P+p.A71V+p.V82T+p.I84V+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, L33IV, M46L, I54V, D60E, L63P, A71V, V82T, I84V, L90M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.V11VI+p.N37S+p.R41K+p.L63PS+p.V77I
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, N37S, R41K, L63PS, V77I.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K20L+p.M46I+p.Q58E+p.I62V+p.L63P+p.A71T+p.T74S+p.V77I+p.N88S+p.L90M+p.Q92K
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20L, M46I, Q58E, I62V, L63P, A71T, T74S, V77I, N88S, L90M, Q92K.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.T4S+p.L10I+p.K20R+p.E35D+p.M36I+p.L63P+p.H69Q+p.L90M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4S, L10I, K20R, E35D, M36I, L63P, H69Q, L90M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.K20R+p.E35D+p.M36I+p.N37D+p.I54V+p.R57K+p.D60E+p.L63P+p.A71V+p.I72T+p.V77VI+p.V82A+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37D, I54V, R57K, D60E, L63P, A71V, I72T, V77VI, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.I62IV+p.L63AP+p.I64IM+p.H69HY+p.K70KR+p.A71AT
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, I62IV, L63AP, I64IM, H69HY, K70KR, A71AT.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10F+p.T12K+p.I13V+p.L19MT+p.K20I+p.M36I+p.R41K+p.M46I+p.I47IV+p.I54V+p.K55R+p.Q58E+p.I62V+p.L63S+p.I64V+p.E65D+p.V82VA
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12K, I13V, L19MT, K20I, M36I, R41K, M46I, I47IV, I54V, K55R, Q58E, I62V, L63S, I64V, E65D, V82VA.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L19I+p.M36MT+p.I62IV+p.L63LP+p.I72M+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, M36MT, I62IV, L63LP, I72M, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.T12P+p.K14R+p.I15IV+p.N37D+p.I62V+p.L63PT+p.C67H+p.A71T+p.V77I+p.Q92QH+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, K14R, I15IV, N37D, I62V, L63PT, C67H, A71T, V77I, Q92QH, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.K20KR+p.M36I+p.R57RK+p.I62V+p.L63P+p.I72IV+p.V82L+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20KR, M36I, R57RK, I62V, L63P, I72IV, V82L, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10V+p.I15V+p.M36I+p.N37D+p.R41K+p.L63S+p.I72T
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, M36I, N37D, R41K, L63S, I72T.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L63P+p.K70R
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, K70R.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.N37D+p.R57G+p.L63P+p.A71AV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57G, L63P, A71AV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.M36I+p.R57G+p.D60DE+p.Q61E+p.I62V+p.L63P+p.A71AT+p.V77VI+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R57G, D60DE, Q61E, I62V, L63P, A71AT, V77VI, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.I13IV+p.K14KR+p.R57G+p.L63P+p.H69Q+p.I72IM+p.V77VI+p.I93IM
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13IV, K14KR, R57G, L63P, H69Q, I72IM, V77VI, I93IM.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.L63LP+p.I64IV+p.K70KR+p.V77VI
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63LP, I64IV, K70KR, V77VI.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.M36I+p.R57G+p.I62IV+p.L63P+p.I64L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, R57G, I62IV, L63P, I64L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57G+p.L63S+p.V77VI+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63S, V77VI, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.R57K+p.Y59YH+p.L63P+p.I72IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, Y59YH, L63P, I72IL.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.R57G+p.I64V
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, I64V.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.L10LI+p.T12TA+p.R57G+p.I62IV+p.L63AST+p.V77VI+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12TA, R57G, I62IV, L63AST, V77VI, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I13IV+p.M36I+p.N37D+p.R57G+p.L63AS
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, M36I, N37D, R57G, L63AS.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.E35D+p.N37D+p.R57G+p.L63P+p.I64IV
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57G, L63P, I64IV.

Key Molecule: HIV1 Protease (HIV1 PR) [3]

• Molecule Alteration: Missense mutation; p.I15V+p.M36I+p.N37D+p.R57G+p.L63P+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, N37D, R57G, L63P, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.M36I+p.R41K+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R41K, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20I+p.E35D+p.M36I+p.R41K+p.I64L+p.H69K+p.V82VI+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, E35D, M36I, R41K, I64L, H69K, V82VI, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10LV+p.I13V+p.K20R+p.M36I+p.N37K+p.R41A+p.H69K+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, I13V, K20R, M36I, N37K, R41A, H69K, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.L10I+p.I13V+p.K14R+p.K20I+p.M36I+p.N37S+p.R41K+p.I64L+p.H69K+p.K70R+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14R, K20I, M36I, N37S, R41K, I64L, H69K, K70R, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.G16E+p.K20R+p.E35D+p.M36I+p.P39PS+p.R41K+p.H69K+p.L89M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, G16E, K20R, E35D, M36I, P39PS, R41K, H69K, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14KR+p.G16E+p.K20R+p.E35D+p.M36I+p.N37X+p.R41K+p.L63LIV+p.H69K+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14KR, G16E, K20R, E35D, M36I, N37X, R41K, L63LIV, H69K, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20I+p.V32VA+p.M36I+p.R41K+p.H69K+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, V32VA, M36I, R41K, H69K, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.G16E+p.K20I+p.E35D+p.M36I+p.R41K+p.M46ML+p.H69K+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, G16E, K20I, E35D, M36I, R41K, M46ML, H69K, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20I+p.E35D+p.M36I+p.R41K+p.H69K+p.V82I+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, E35D, M36I, R41K, H69K, V82I, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13IV+p.K14KR+p.E35D+p.M36I+p.N37ND+p.R41K+p.D60DE+p.Q61QE+p.I62IV+p.L63X+p.I64ILM+p.C67CY+p.H69K+p.L89M+p.I93IL
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, K14KR, E35D, M36I, N37ND, R41K, D60DE, Q61QE, I62IV, L63X, I64ILM, C67CY, H69K, L89M, I93IL.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I15V+p.M36I+p.N37S+p.R41K+p.L63P+p.H69K+p.L89M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, N37S, R41K, L63P, H69K, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.I13V+p.K14R+p.K20IV+p.M36I+p.N37ND+p.R41K+p.L63S+p.H69K+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20IV, M36I, N37ND, R41K, L63S, H69K, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.T12S+p.L19I+p.M36I+p.R41K+p.L63V+p.H69K+p.T74S+p.V77I+p.L89M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, L19I, M36I, R41K, L63V, H69K, T74S, V77I, L89M, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [8]

• Molecule Alteration: Missense mutation; p.T12S+p.I15V+p.L19I+p.M36I+p.R41K+p.L63V+p.H69K+p.K70R+p.P79PT+p.L89M
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I15V, L19I, M36I, R41K, L63V, H69K, K70R, P79PT, L89M.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10LI+p.L24I+p.R41K+p.M46L+p.I54V+p.I62V+p.L63P+p.A71V+p.T74A+p.V77I+p.V82A+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L24I, R41K, M46L, I54V, I62V, L63P, A71V, T74A, V77I, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.V32I+p.I47V+p.Q61E+p.L63P+p.V82A+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V32I, I47V, Q61E, L63P, V82A, I93L.

Key Molecule: HIV1 Protease (HIV1 PR) [9]

• Molecule Alteration: Missense mutation; p.L10LI+p.I15IV+p.G17DE+p.K20IMR+p.R41RK+p.I62IV+p.L63P+p.A71V+p.G73X+p.V77VI+p.I84IV+p.I85IV+p.L90M+p.I93L
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
• Experiment for Drug Resistance: PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
• Mechanism Description: Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I15IV, G17DE, K20IMR, R41RK, I62IV, L63P, A71V, G73X, V77VI, I84IV, I85IV, L90M, I93L.

Drug Inactivation by Structure Modification (DISM)

Key Molecule: Cytochrome P450 family 3 subfamily A (CYP3A) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Darunavir, a HIV PI that is co-administered with low-dose ritonavir (darunavir/ritonavir), is recommended in combination with other antiretrovirals. The mechanism of ritonavir pharmacokinetic enhancement is through inhibiting cytochrome P450 (CYP) 3A. Ritonavir has intrinsic antiviral activity against HIV-1 when administered at high doses (i.e., 600 mg twice daily) and was the second PI to be licensed. Along with saquinavir and indinavir, it heralded the advent of highly active antiretroviral therapy.

References

• Ref 1: Darunavir/cobicistat once daily for the treatment of HIV. Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400.
• Ref 2: Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017.
• Ref 3: HIV-1 protease mutations and protease inhibitor cross-resistanceAntimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.
• Ref 4: Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, UgandaAIDS. 2009 Apr 27;23(7):845-52. doi: 10.1097/QAD.0b013e328327957a.
• Ref 5: Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlatesJ Virol. 2005 Mar;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005.
• Ref 6: HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceJ Infect Dis. 2005 Aug 1;192(3):456-65. doi: 10.1086/431601. Epub 2005 Jul 5.
• Ref 7: Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsJ Virol. 2001 Aug;75(16):7462-9. doi: 10.1128/JVI.75.16.7462-7469.2001.
• Ref 8: Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypesAIDS. 2008 Mar 12;22(5):611-6. doi: 10.1097/QAD.0b013e3282f51eb9.
• Ref 9: Phenotypic susceptibility to TMC-114 and tipranavir before and after lopinavir/ritonavir-based treatment in subjects demonstrating evolution of lopinavir resistance.
• Ref 10: Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol. 2015 Nov 11;90(2):1062-9. doi: 10.1128/JVI.01772-15. Print 2016 Jan 15.